

Alessandro Serretti

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9270708/alessandro-serretti-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

691 papers	25,313 citations	73 h-index	129 g-index
831 ext. papers	29,543 ext. citations	4.8 avg, IF	7.27 L-index

#	Paper	IF	Citations
691	The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries.. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2022 , 1	5.1	2
690	Metabolizing status of CYP2C19 in response and side effects to medications for depression: Results from a naturalistic study.. <i>European Neuropsychopharmacology</i> , 2022 , 56, 100-111	1.2	2
689	Transcriptional biomarkers of response to pharmacological treatments in severe mental disorders: A systematic review.. <i>European Neuropsychopharmacology</i> , 2022 , 55, 112-157	1.2	2
688	Pregabalin augmentation of antidepressants in major depression - results from a European multicenter study. <i>Journal of Affective Disorders</i> , 2022 , 296, 485-492	6.6	
687	Seasonality in Major Depressive Disorder: Effect of Sex and Age. <i>Journal of Affective Disorders</i> , 2022 , 296, 111-116	6.6	1
686	Insulinopathies of the brain? Genetic overlap between somatic insulin-related and neuropsychiatric disorders.. <i>Translational Psychiatry</i> , 2022 , 12, 59	8.6	1
685	Precision medicine in mood disorders 2022 , 1,		0
684	Imputed expression of schizophrenia-associated genes and cognitive measures in patients with schizophrenia.. <i>Molecular Genetics & Genomic Medicine</i> , 2022 , e1942	2.3	0
683	Depression, antidepressants, and insulin resistance: which link?. <i>European Neuropsychopharmacology</i> , 2022 , 60, 4-6	1.2	0
682	The U-shaped relationship between parental age and the risk of bipolar disorder in the offspring: A systematic review and meta-analysis. <i>European Neuropsychopharmacology</i> , 2022 , 60, 55-75	1.2	0
681	Expert consensus recommendations on the use of randomized clinical trials for drug approval in psychiatry- comparing trial designs. <i>European Neuropsychopharmacology</i> , 2022 , 60, 91-99	1.2	1
680	A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response. <i>European Neuropsychopharmacology</i> , 2021 , 55, 86-95	1.2	3
679	Evidence on sociodemographic and clinical correlates of antidepressant combination or augmentation with second-generation antipsychotics in major depressive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021 , 114, 110480	5.5	1
678	The Choice of either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients with Major Depressive Disorder. <i>International Journal of Neuropsychopharmacology</i> , 2021 ,	5.8	1
677	Genetic and clinical characteristics of treatment-resistant depression using primary care records in two UK cohorts. <i>Molecular Psychiatry</i> , 2021 , 26, 3363-3373	15.1	20
676	Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. <i>Nature Genetics</i> , 2021 , 53, 817-829	36.3	83
675	The Role of Relationship Status in Major Depressive Disorder - Results of the European Group for the Study of Resistant Depression. <i>Journal of Affective Disorders</i> , 2021 , 286, 149-157	6.6	3

674	Genetic underpinnings of sociability in the general population. <i>Neuropsychopharmacology</i> , 2021 , 46, 1628-1634	7.1	1
673	The association of childhood trauma, lifetime stressful events and general psychopathological symptoms in euthymic bipolar patients and healthy subjects. <i>Journal of Affective Disorders</i> , 2021 , 289, 66-73	6.6	1
672	Venlafaxine and O-desmethylenlafaxine serum levels are positively associated with antidepressant response in elder depressed out-patients. <i>World Journal of Biological Psychiatry</i> , 2021 , 1-8	3.8	2
671	Transcriptome-wide association study of treatment-resistant depression and depression subtypes for drug repurposing. <i>Neuropsychopharmacology</i> , 2021 , 46, 1821-1829	8.7	5
670	Pharmacogenetic-Guided Treatment of Depression: Real-World Clinical Applications, Challenges, and Perspectives. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 110, 573-581	6.1	4
669	Mindfulness-Based Cognitive Therapy vs. Psycho-education for Patients with Anxiety Disorders Who Did Not Achieve Remission Following Adequate Pharmacological Treatment. <i>Mindfulness</i> , 2021 , 12, 2059-2075	2.9	0
668	Genome-wide association identifies the first risk loci for psychosis in Alzheimer disease. <i>Molecular Psychiatry</i> , 2021 ,	15.1	5
667	Sex-related effects in major depressive disorder: Results of the European Group for the Study of Resistant Depression. <i>Depression and Anxiety</i> , 2021 , 38, 896-906	8.4	5
666	Gastrointestinal side effects associated with antidepressant treatments in patients with major depressive disorder: A systematic review and meta-analysis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021 , 109, 110266	5.5	4
665	Drug repositioning for treatment-resistant depression: Hypotheses from a pharmacogenomic study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021 , 104, 110050	5.5	6
664	Cost-effectiveness of genetic and clinical predictors for choosing combined psychotherapy and pharmacotherapy in major depression. <i>Journal of Affective Disorders</i> , 2021 , 279, 722-729	6.6	2
663	Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021 , 108, 110170	5.5	9
662	Precision psychiatry in clinical practice. <i>International Journal of Psychiatry in Clinical Practice</i> , 2021 , 25, 19-27	2.4	7
661	Irritable Mood and Subthreshold Hypomanic Episodes Correlate with More Severe Major Depression. <i>Neuropsychobiology</i> , 2021 , 80, 425-436	4	1
660	Possible Modulatory Role of ARC Gene Variants in Mood Disorders. <i>Clinical Psychopharmacology and Neuroscience</i> , 2021 , 19, 46-52	3.4	2
659	A Practical Utility and Benefit of Pharmacogenetic-based Antidepressant Treatment Strategy for Major Depressive Disorder Patients with Difficult-to-treat. <i>Clinical Psychopharmacology and Neuroscience</i> , 2021 , 19, 160-165	3.4	2
658	Melancholic features in major depression - a European multicenter study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021 , 110, 110285	5.5	3
657	Research Domain Criteria (RDoC): A Perspective to Probe the Biological Background behind Treatment Efficacy in Depression. <i>Current Medicinal Chemistry</i> , 2021 , 28, 4296-4320	4.3	1

656	Identifying the Common Genetic Basis of Antidepressant Response. <i>Biological Psychiatry Global Open Science</i> , 2021 ,		4
655	Switch to 3-Month Long-Acting Injectable Paliperidone May Decrease Plasma Levels: A Case Series. <i>Journal of Clinical Psychopharmacology</i> , 2021 , 41, 694-696	1.7	0
654	Combining psychopharmacotherapy and psychotherapy is not associated with better treatment outcome in major depressive disorder - evidence from the European Group for the Study of Resistant Depression. <i>Journal of Psychiatric Research</i> , 2021 , 141, 167-175	5.2	3
653	Dissecting the Shared Genetic Architecture of Suicide Attempt, Psychiatric Disorders, and Known Risk Factors. <i>Biological Psychiatry</i> , 2021 ,	7.9	11
652	Antidepressant efficacy is correlated with plasma levels: mega-analysis and further evidence.. <i>International Clinical Psychopharmacology</i> , 2021 , 37,	2.2	2
651	P.0882 A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response. <i>European Neuropsychopharmacology</i> , 2021 , 53, S646-S647	1.2	
650	Interleukin-1 Beta in Peripheral Blood Mononuclear Cell Lysates as a Longitudinal Biomarker of Response to Antidepressants: A Pilot Study.. <i>Frontiers in Psychiatry</i> , 2021 , 12, 801738	5	
649	Serum Aripiprazole Concentrations Prehemodialysis and Posthemodialysis in a Schizophrenic Patient With Chronic Renal Failure: A Case Report. <i>Journal of Clinical Psychopharmacology</i> , 2020 , 40, 200-202	1.7	2
648	A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotyping. <i>Translational Psychiatry</i> , 2020 , 10, 50	8.6	16
647	Genetic variants associated with psychotic symptoms across psychiatric disorders. <i>Neuroscience Letters</i> , 2020 , 720, 134754	3.3	4
646	The black sheep of the family- whole-exome sequencing in family of lithium response discordant bipolar monozygotic twins. <i>European Neuropsychopharmacology</i> , 2020 , 34, 19-27	1.2	4
645	The search for personalized antidepressant treatments: what have we learned and where are we going. <i>Pharmacogenomics</i> , 2020 , 21, 1095-1100	2.6	2
644	Genetics of Treatment Outcomes in Major Depressive Disorder: Present and Future. <i>Clinical Psychopharmacology and Neuroscience</i> , 2020 , 18, 1-9	3.4	18
643	Gene Variants Have a Cross-diagnostic Influence on Psychosis and Treatment Improvement in Mood Disorders. <i>Clinical Psychopharmacology and Neuroscience</i> , 2020 , 18, 231-240	3.4	4
642	How to Utilize Clinical and Genetic Information for Personalized Treatment of Major Depressive Disorder: Step by Step Strategic Approach. <i>Clinical Psychopharmacology and Neuroscience</i> , 2020 , 18, 484-492	3.4	11
641	Antidepressants: Indications, Contraindications, Interactions, and Side Effects 2020 , 1-38		2
640	Reduced plasma Fetuin-A is a promising biomarker of depression in the elderly. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020 , 270, 901-910	5.1	4
639	Social dysfunction in mood disorders and schizophrenia: Clinical modulators in four independent samples. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020 , 99, 109835	5.5	7

638	Cortico-limbic functional connectivity mediates the effect of early life stress on suicidality in bipolar depressed 5-HTTLPR*s carriers. <i>Journal of Affective Disorders</i> , 2020 , 263, 420-427	6.6	5
637	Pharmacogenetics in Psychiatry: An Update on Clinical Usability. <i>Frontiers in Pharmacology</i> , 2020 , 11, 575540	5.6	23
636	Add-on benzodiazepine treatment in patients with major depressive disorder - results from a European cross-sectional multicenter study. <i>European Neuropsychopharmacology</i> , 2020 , 41, 70-80	1.2	9
635	Genetics and major depressive disorder: clinical implications for disease risk, prognosis and treatment. <i>International Clinical Psychopharmacology</i> , 2020 , 35, 233-242	2.2	11
634	Clinical Correlates and Outcome of Major Depressive Disorder and Comorbid Migraine: A Report of the European Group for the Study of Resistant Depression. <i>International Journal of Neuropsychopharmacology</i> , 2020 , 23, 571-577	5.8	2
633	Clinical application of antidepressant pharmacogenetics: Considerations for the design of future studies. <i>Neuroscience Letters</i> , 2020 , 726, 133651	3.3	12
632	Association between CANCA1C gene rs1034936 polymorphism and alcohol dependence in bipolar disorder. <i>Journal of Affective Disorders</i> , 2020 , 261, 181-186	6.6	7
631	Lithium Exposure During Pregnancy and the Postpartum Period: A Systematic Review and Meta-Analysis of Safety and Efficacy Outcomes. <i>American Journal of Psychiatry</i> , 2020 , 177, 76-92	11.9	43
630	Genetics of resilience: Implications from genome-wide association studies and candidate genes of the stress response system in posttraumatic stress disorder and depression. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2020 , 183, 77-94	3.5	26
629	Psychiatric disorders and SLC6A4 gene variants: possible effects on alcohol dependence and alzheimer's disease. <i>Molecular Biology Reports</i> , 2020 , 47, 191-200	2.8	3
628	New-generation, non-SSRI antidepressants: Drug-drug interactions and therapeutic drug monitoring. Part 2: NaSSAs, NRIs, SNDRI, MASSAs, NDRI, and others. <i>Medicinal Research Reviews</i> , 2020 , 40, 1794-1832	14.4	13
627	Manifesto for an international digital mental health network 2019 , 2, 14-24		11
626	High occupational level is associated with poor response to the treatment of depression: A replication study. <i>European Neuropsychopharmacology</i> , 2019 , 29, 349-355	1.2	2
625	Alzheimer's Disease and Neurotransmission Gene Variants: Focus on Their Effects on Psychiatric Comorbidities and Inflammatory Parameters. <i>Neuropsychobiology</i> , 2019 , 78, 79-85	4	6
624	The brief assessment of cognition in affective disorders: Normative data for the Italian population. <i>Journal of Affective Disorders</i> , 2019 , 252, 245-252	6.6	4
623	FKBP5 Gene Variants May Modulate Depressive Features in Bipolar Disorder. <i>Neuropsychobiology</i> , 2019 , 78, 104-112	4	0
622	Major Depression and Comorbid Diabetes - Findings from the European Group for the Study of Resistant Depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019 , 94, 109638	5.5	11
621	Genome-wide association study identifies 30 loci associated with bipolar disorder. <i>Nature Genetics</i> , 2019 , 51, 793-803	36.3	662

620	Comorbid hypertension in patients with major depressive disorder - Results from a European multicenter study. <i>European Neuropsychopharmacology</i> , 2019 , 29, 777-785	1.2	12
619	The influence of the serotonin transporter gene 5-HTTLPR polymorphism on suicidal behavior: a meta-analysis. <i>European Neuropsychopharmacology</i> , 2019 , 29, S278-S279	1.2	
618	Temperament and character influence on depression treatment outcome. <i>Journal of Affective Disorders</i> , 2019 , 252, 464-474	6.6	14
617	Single nucleotide polymorphisms (SNPs) implicated in determining predominant polarity in bipolar disorder. <i>European Neuropsychopharmacology</i> , 2019 , 29, S378-S379	1.2	
616	Predominant polarity in bipolar disorder patients: The COPE bipolar sample. <i>Journal of Affective Disorders</i> , 2019 , 250, 43-50	6.6	10
615	White Matter Microstructure in Bipolar Disorder Is Influenced by the Interaction between a Glutamate Transporter EAAT1 Gene Variant and Early Stress. <i>Molecular Neurobiology</i> , 2019 , 56, 702-710	6.2	30
614	The influence of the serotonin transporter gene 5-HTTLPR polymorphism on suicidal behaviors: a meta-analysis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019 , 88, 375-387	5.5	26
613	Genetic basis of psychopathological dimensions shared between schizophrenia and bipolar disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019 , 89, 23-29	5.5	6
612	Results of the European Group for the Study of Resistant Depression (GSRD) - basis for further research and clinical practice. <i>World Journal of Biological Psychiatry</i> , 2019 , 20, 427-448	3.8	51
611	Is Pharmacogenetics Useful in Antidepressant Treatment?. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 106, 916-918	6.1	1
610	Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. <i>European Neuropsychopharmacology</i> , 2019 , 29, 971-985	1.2	44
609	Pharmacogenetics and Depression: A Critical Perspective. <i>Psychiatry Investigation</i> , 2019 , 16, 645-653	3.1	9
608	Psychotic Features in Patients With Major Depressive Disorder: A Report From the European Group for the Study of Resistant Depression. <i>Journal of Clinical Psychiatry</i> , 2019 , 80,	4.6	18
607	Genes Involved in Neurodevelopment, Neuroplasticity and Major Depression: No Association for and. <i>Clinical Psychopharmacology and Neuroscience</i> , 2019 , 17, 364-368	3.4	8
606	Reduced CXCL1/GRO chemokine plasma levels are a possible biomarker of elderly depression. <i>Journal of Affective Disorders</i> , 2019 , 249, 410-417	6.6	5
605	Personalized and precision medicine as informants for treatment management of bipolar disorder. <i>International Clinical Psychopharmacology</i> , 2019 , 34, 189-205	2.2	11
604	Attrition in treatment-resistant depression: predictors and clinical impact. <i>International Clinical Psychopharmacology</i> , 2019 , 34, 161-169	2.2	
603	Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders. <i>Cell</i> , 2019 , 179, 1469-1482.e11	56.2	402

602	Corrected QT Interval Prolongation in Psychopharmacological Treatment and Its Modulation by Genetic Variation. <i>Neuropsychobiology</i> , 2019 , 77, 67-72	4	5
601	Relating constructs of attention and working memory to social withdrawal in Alzheimer's disease and schizophrenia: issues regarding paradigm selection. <i>Neuroscience and Biobehavioral Reviews</i> , 2019 , 97, 47-69	9	15
600	Biallelic variants in FBXL3 cause intellectual disability, delayed motor development and short stature. <i>Human Molecular Genetics</i> , 2019 , 28, 972-979	5.6	9
599	Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples. <i>British Journal of Psychiatry</i> , 2019 , 214, 36-41	5.4	24
598	Duloxetine plasma level and antidepressant response. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019 , 92, 127-132	5.5	17
597	Opinion paper: poor response to treatment of depression in people in high occupational levels. <i>Psychological Medicine</i> , 2019 , 49, 49-54	6.9	6
596	Social brain, social dysfunction and social withdrawal. <i>Neuroscience and Biobehavioral Reviews</i> , 2019 , 97, 10-33	9	96
595	Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study. <i>Acta Psychiatrica Scandinavica</i> , 2019 , 139, 78-88	6.5	52
594	A quantitative approach to neuropsychiatry: The why and the how. <i>Neuroscience and Biobehavioral Reviews</i> , 2019 , 97, 3-9	9	47
593	The Genetics of Treatment-Resistant Depression: A Critical Review and Future Perspectives. <i>International Journal of Neuropsychopharmacology</i> , 2019 , 22, 93-104	5.8	14
592	Major Depression and the Degree of Suicidality: Results of the European Group for the Study of Resistant Depression (GSRD). <i>International Journal of Neuropsychopharmacology</i> , 2018 , 21, 539-549	5.8	32
591	Clinical correlates of augmentation/combination treatment strategies in major depressive disorder. <i>Acta Psychiatrica Scandinavica</i> , 2018 , 137, 401-412	6.5	25
590	Deiodinases, Organic Anion Transporter Polypeptide Polymorphisms, and Thyroid Hormones in Patients with Myocardial Infarction. <i>Genetic Testing and Molecular Biomarkers</i> , 2018 , 22, 270-278	1.6	5
589	Hot Genes in Schizophrenia: How Clinical Datasets Could Help to Refine their Role. <i>Journal of Molecular Neuroscience</i> , 2018 , 64, 273-286	3.3	4
588	Highlights on Pharmacogenetics and Pharmacogenomics in Depression 2018 , 3-16		
587	Comorbid thyroid disease in patients with major depressive disorder - results from the European Group for the Study of Resistant Depression (GSRD). <i>European Neuropsychopharmacology</i> , 2018 , 28, 752-760	12.2	25
586	Collaborative meta-analysis finds no evidence of a strong interaction between stress and 5-HTTLPR genotype contributing to the development of depression. <i>Molecular Psychiatry</i> , 2018 , 23, 133-142	15.1	188
585	Low comorbid obsessive-compulsive disorder in patients with major depressive disorder - Findings from a European multicenter study. <i>Journal of Affective Disorders</i> , 2018 , 227, 254-259	6.6	5

584	Pleiotropic genes in psychiatry: Calcium channels and the stress-related FKBP5 gene in antidepressant resistance. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018 , 81, 203-210	5.5	20
583	Expansion and further delineation of the SETD5 phenotype leading to global developmental delay, variable dysmorphic features, and reduced penetrance. <i>Clinical Genetics</i> , 2018 , 93, 752-761	4	11
582	A Glutamate Transporter EAAT1 Gene Variant Influences Amygdala Functional Connectivity in Bipolar Disorder. <i>Journal of Molecular Neuroscience</i> , 2018 , 65, 536-545	3.3	31
581	The association between electrodermal activity (EDA), depression and suicidal behaviour: A systematic review and narrative synthesis. <i>BMC Psychiatry</i> , 2018 , 18, 22	4.2	62
580	Pharmacogenetics in Psychiatry. <i>Advances in Pharmacology</i> , 2018 , 83, 297-331	5.7	16
579	22q11.2 rearrangements: clinical and research implications of population-based risk of neuropsychiatric and developmental disorders. <i>Lancet Psychiatry</i> , 2018 , 5, 531-532	23.3	0
578	Refining Prediction in Treatment-Resistant Depression: Results of Machine Learning Analyses in the TRD III Sample. <i>Journal of Clinical Psychiatry</i> , 2018 , 79,	4.6	58
577	The Present and Future of Precision Medicine in Psychiatry: Focus on Clinical Psychopharmacology of Antidepressants. <i>Clinical Psychopharmacology and Neuroscience</i> , 2018 , 16, 1-6	3.4	43
576	A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial. <i>Clinical Psychopharmacology and Neuroscience</i> , 2018 , 16, 469-480	3.4	15
575	Genetic Variants Within Molecular Targets of Antipsychotic Treatment: Effects on Treatment Response, Schizophrenia Risk, and Psychopathological Features. <i>Journal of Molecular Neuroscience</i> , 2018 , 64, 62-74	3.3	3
574	Early improvement and response to antidepressant medications in adults with major depressive disorder. Meta-analysis and study of a sample with treatment-resistant depression. <i>Journal of Affective Disorders</i> , 2018 , 227, 777-786	6.6	20
573	The serotonin transporter and the activity regulated cytoskeleton-associated protein genes in antidepressant response and resistance: 5-HTTLPR and other variants. <i>Human Psychopharmacology</i> , 2018 , 33, e2682	2.3	6
572	Clinical factors associated with augmentation treatment with second-generation antipsychotics and lithium in major depression - Results from a European multicenter study. <i>European Neuropsychopharmacology</i> , 2018 , 28, 1305-1313	1.2	13
571	Brexipiprazole: a step forward for precision medicine in resistant depression. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 1817-1819	4	1
570	Neuroplasticity, Neurotransmission and Brain-Related Genes in Major Depression and Bipolar Disorder: Focus on Treatment Outcomes in an Asiatic Sample. <i>Advances in Therapy</i> , 2018 , 35, 1656-1670	4.1	9
569	Pharmacogenetic tests to guide drug treatment in depression: Comparison of the available testing kits and clinical trials. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018 , 86, 36-44	5.5	30
568	Genetics of schizophrenia: A consensus paper of the WFSBP Task Force on Genetics. <i>World Journal of Biological Psychiatry</i> , 2017 , 18, 492-505	3.8	33
567	The Impact of a Single Nucleotide Polymorphism in SIGMAR1 on Depressive Symptoms in Major Depressive Disorder and Bipolar Disorder. <i>Advances in Therapy</i> , 2017 , 34, 713-724	4.1	10

566	Maoa and Maob polymorphisms and personality traits in suicide attempters and healthy controls: a preliminary study. <i>Psychiatry Research</i> , 2017 , 249, 212-217	9.9	4
565	Clinical characteristics and treatment outcomes of patients with major depressive disorder and comorbid anxiety disorders - results from a European multicenter study. <i>Journal of Psychiatric Research</i> , 2017 , 91, 1-13	5.2	46
564	Non response at week 4 as clinically useful indicator for antidepressant combination in major depressive disorder. A sequential RCT. <i>Journal of Psychiatric Research</i> , 2017 , 89, 97-104	5.2	10
563	Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017 , 267, 723-735	5.1	14
562	Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia: systematic review and indirect treatment comparison. <i>International Clinical Psychopharmacology</i> , 2017 , 32, 235-248	2.2	16
561	Electrocardiogram Alterations Associated With Psychotropic Drug Use and CACNA1C Gene Variants in Three Independent Samples. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2017 , 120, 482-490	3.1	6
560	Genetic Variants Within Key Nodes of the Cascade of Antipsychotic Mechanisms: Effects on Antipsychotic Response and Schizophrenia Psychopathology in a Naturalistic Treatment Setting in Two Independent Korean and Italian Samples. <i>Advances in Therapy</i> , 2017 , 34, 1482-1497	4.1	3
559	The impact of comorbid post-traumatic stress disorder in patients with major depressive disorder on clinical features, pharmacological treatment strategies, and treatment outcomes - Results from a cross-sectional European multicenter study. <i>European Neuropsychopharmacology</i> , 2017 , 27, 625-632	1.2	14
558	Nine differentially expressed genes from a post mortem study and their association with suicidal status in a sample of suicide completers, attempters and controls. <i>Journal of Psychiatric Research</i> , 2017 , 91, 98-104	5.2	4
557	The Impact of BDNF Polymorphisms on Suicidality in Treatment-Resistant Major Depressive Disorder: A European Multicenter Study. <i>International Journal of Neuropsychopharmacology</i> , 2017 , 20, 782-787	5.8	8
556	Cariprazine specificity profile in the treatment of acute schizophrenia: a meta-analysis and meta-regression of randomized-controlled trials. <i>International Clinical Psychopharmacology</i> , 2017 , 32, 309-318	2.2	16
555	Role of 108 schizophrenia-associated loci in modulating psychopathological dimensions in schizophrenia and bipolar disorder. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2017 , 174, 757-764	3.5	22
554	Escitalopram plasma levels and antidepressant response. <i>European Neuropsychopharmacology</i> , 2017 , 27, 940-944	1.2	34
553	Prescribing patterns of psychiatric drugs in major depressive disorder [Findings from a large European multicenter, cross-sectional study. <i>European Psychiatry</i> , 2017 , 41, S367-S367	6	
552	Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response. <i>World Journal of Biological Psychiatry</i> , 2017 , 18, 5-28	3.8	54
551	Role of 108 schizophrenia-associated loci in modulating psychopathological dimensions in schizophrenia and bipolar disorder. <i>European Neuropsychopharmacology</i> , 2017 , 27, S583	1.2	
550	Potential genes behind the difference between bipolar I and bipolar II disorder. <i>European Neuropsychopharmacology</i> , 2017 , 27, S836-S837	1.2	
549	Association between CACNA1C gene rs1034936 polymorphism and alcoholism in bipolar disorder. <i>European Neuropsychopharmacology</i> , 2017 , 27, S1057-S1058	1.2	

548	Temperament and Character Inventory in Bipolar Disorder versus Healthy Controls and Modulatory Effects of 3 Key Functional Gene Variants. <i>Neuropsychobiology</i> , 2017 , 76, 209-221	4	7
547	Genetics and pharmacogenetics of mood disorders. <i>Psychiatria Polska</i> , 2017 , 51, 197-203	1.3	7
546	A New Prediction Model for Evaluating Treatment-Resistant Depression. <i>Journal of Clinical Psychiatry</i> , 2017 , 78, 215-222	4.6	49
545	Association between Sirtuin 1 Gene rs10997870 Polymorphism and Suicide Behaviors in Bipolar Disorder. <i>Neuropsychobiology</i> , 2016 , 74, 1-7	4	12
544	Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial. <i>BMC Psychiatry</i> , 2016 , 16, 172	4.2	11
543	Pharmacological treatment strategies in unipolar depression in European tertiary psychiatric treatment centers - A pharmacoepidemiological cross-sectional multicenter study. <i>European Neuropsychopharmacology</i> , 2016 , 26, 1960-1971	1.2	33
542	Is long-acting injectable aripiprazole useful for the treatment of acute exacerbation of schizophrenia?. <i>Evidence-Based Mental Health</i> , 2016 , 19, e25	11.1	
541	Progress and prospects in pharmacogenetics of antidepressant drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016 , 12, 1157-68	5.5	22
540	Polymorphism of rs3813034 in Serotonin Transporter Gene SLC6A4 Is Associated With the Selective Serotonin and Serotonin-Norepinephrine Reuptake Inhibitor Response in Depressive Disorder: Sequencing Analysis of SLC6A4. <i>Journal of Clinical Psychopharmacology</i> , 2016 , 36, 27-31	1.7	8
539	Bipolar II disorder as a risk factor for postpartum depression. <i>Journal of Affective Disorders</i> , 2016 , 204, 54-8	6.6	22
538	Genome-wide association study of antidepressant response: involvement of the inorganic cation transmembrane transporter activity pathway. <i>BMC Psychiatry</i> , 2016 , 16, 106	4.2	19
537	Hippocampal Pruning as a New Theory of Schizophrenia Etiopathogenesis. <i>Molecular Neurobiology</i> , 2016 , 53, 2065-2081	6.2	22
536	Pharmacogenetics of clozapine response and induced weight gain: A comprehensive review and meta-analysis. <i>European Neuropsychopharmacology</i> , 2016 , 26, 163-185	1.2	37
535	5-HTTLPR and gender differences in affective disorders: A systematic review. <i>Journal of Affective Disorders</i> , 2016 , 190, 193-207	6.6	37
534	Clinical and genetic factors associated with suicide in mood disorder patients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2016 , 266, 181-93	5.1	25
533	The microtubule-associated molecular pathways may be genetically disrupted in patients with Bipolar Disorder. Insights from the molecular cascades. <i>Journal of Affective Disorders</i> , 2016 , 190, 429-438	6.6	10
532	Remifentanyl in electroconvulsive therapy: a systematic review and meta-analysis of randomized controlled trials. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2016 , 266, 703-717	5.1	17
531	Pharmacogenetics of the Efficacy and Side Effects of Antidepressant Drugs 2016 , 39-54		1

530	The Comparative Effects of Risperidone Long-Acting Injection and Paliperidone Palmitate on Social Functioning in Schizophrenia: A 6-Month, Open-Label, Randomized Controlled Pilot Trial. <i>Neuropsychobiology</i> , 2016 , 73, 35-42	4	18
529	Glutamatergic and HPA-axis pathway genes in bipolar disorder comorbid with alcohol- and substance use disorders. <i>Metabolic Brain Disease</i> , 2016 , 31, 183-9	3.9	5
528	Socio-demographic and clinical predictors of treatment resistant depression: A prospective European multicenter study. <i>Journal of Affective Disorders</i> , 2016 , 189, 224-32	6.6	54
527	Genetics of long-term treatment outcome in bipolar disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016 , 65, 17-24	5.5	26
526	Age of Onset in Schizophrenia Spectrum Disorders: Complex Interactions between Genetic and Environmental Factors. <i>Psychiatry Investigation</i> , 2016 , 13, 247-9	3.1	7
525	The Role of Pharmacogenetics in Pharmacovigilance of Psychotropic Drugs 2016 , 121-146		
524	Practical Application of Pharmacogenetics of Antipsychotic, Antidepressant, and Mood-Stabilizing Drugs 2016 , 111-117		
523	Adenosine Hypothesis of Antipsychotic Drugs Revisited: Pharmacogenomics Variation in Nonacute Schizophrenia. <i>OMICS A Journal of Integrative Biology</i> , 2016 , 20, 283-9	3.8	15
522	The impact of serotonin receptor 1A and 2A gene polymorphisms and interactions on suicide attempt and suicide risk in depressed patients with insufficient response to treatment--a European multicentre study. <i>International Clinical Psychopharmacology</i> , 2016 , 31, 1-7	2.2	16
521	Genes Involved in Neurodevelopment, Neuroplasticity, and Bipolar Disorder: CACNA1C, CHRNA1, and MAPK1. <i>Neuropsychobiology</i> , 2016 , 74, 159-168	4	14
520	ECG alterations associated with psychotropic drug use in clinical settings: clinical and genetic predictors. <i>European Neuropsychopharmacology</i> , 2016 , 26, S240-S241	1.2	
519	Epidemiology of psychopharmacological options in unipolar major depression in European tertiary psychiatric treatment centers. <i>European Neuropsychopharmacology</i> , 2016 , 26, S417-S418	1.2	
518	A meta-analysis of cognitive performance in melancholic versus non-melancholic unipolar depression. <i>Journal of Affective Disorders</i> , 2016 , 201, 15-24	6.6	35
517	Possible biomarkers modulating haloperidol efficacy and/or tolerability. <i>Pharmacogenomics</i> , 2016 , 17, 507-29	2.6	
516	Clinical factors related to schizophrenia relapse. <i>International Journal of Psychiatry in Clinical Practice</i> , 2016 , 20, 54-69	2.4	20
515	HTR1A Polymorphisms and Clinical Efficacy of Antipsychotic Drug Treatment in Schizophrenia: A Meta-Analysis. <i>International Journal of Neuropsychopharmacology</i> , 2016 , 19,	5.8	18
514	PDE7B, NMBR and EPM2A Variants and Schizophrenia: A Case-Control and Pharmacogenetics Study. <i>Neuropsychobiology</i> , 2016 , 73, 160-8	4	8
513	Socio-demographic and clinical predictors of non-response/non-remission in treatment resistant depressed patients: A systematic review. <i>Psychiatry Research</i> , 2016 , 240, 421-430	9.9	94

512	Role of neurodevelopment involved genes in psychiatric comorbidities and modulation of inflammatory processes in Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 2016 , 370, 162-166	3.2	7
511	High occupational level is associated with poor response to treatment of depression. <i>European Neuropsychopharmacology</i> , 2016 , 26, 1320-6	1.2	7
510	What to expect from a third step in treatment resistant depression: A prospective open study on escitalopram. <i>World Journal of Biological Psychiatry</i> , 2015 , 16, 472-82	3.8	14
509	A model to investigate SNPs' interaction in GWAS studies. <i>Journal of Neural Transmission</i> , 2015 , 122, 145-53	4.3	3
508	CHL1, ITGB3 and SLC6A4 gene expression and antidepressant drug response: results from the Munich Antidepressant Response Signature (MARS) study. <i>Pharmacogenomics</i> , 2015 , 16, 689-701	2.6	19
507	The role of specific early trauma in adult depression: A meta-analysis of published literature. Childhood trauma and adult depression. <i>European Psychiatry</i> , 2015 , 30, 665-80	6	252
506	Genetic variability in tryptophan hydroxylase 2 gene in alcohol dependence and alcohol-related psychopathological symptoms. <i>Neuroscience Letters</i> , 2015 , 604, 86-90	3.3	7
505	Genes involved in pruning and inflammation are enriched in a large mega-sample of patients affected by Schizophrenia and Bipolar Disorder and controls. <i>Psychiatry Research</i> , 2015 , 228, 945-9	9.9	19
504	Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015 , 265, 579-88	5.1	3
503	Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder. <i>Journal of Psychiatry and Neuroscience</i> , 2015 , 40, 174-86	4.5	43
502	The influence of AHI1 variants on the diagnosis and treatment outcome in schizophrenia. <i>International Journal of Molecular Sciences</i> , 2015 , 16, 2517-29	6.3	11
501	Neuronal cell adhesion genes and antidepressant response in three independent samples. <i>Pharmacogenomics Journal</i> , 2015 , 15, 538-48	3.5	25
500	Enrichment pathway analysis. The inflammatory genetic background in Bipolar Disorder. <i>Journal of Affective Disorders</i> , 2015 , 179, 88-94	6.6	29
499	Predictors of switch from depression to mania in bipolar disorder. <i>Journal of Psychiatric Research</i> , 2015 , 66-67, 45-53	5.2	22
498	Il trattamento antidepressivo: effetti sul peso corporeo. <i>L Endocrinologo</i> , 2015 , 16, 22-25	0	
497	Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTs. <i>Translational Psychiatry</i> , 2015 , 5, e513	8.6	12
496	Mindfulness-based cognitive therapy vs. psycho-education for patients with major depression who did not achieve remission following antidepressant treatment. <i>Psychiatry Research</i> , 2015 , 226, 474-83	9.9	44
495	Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: a systematic review and meta-analysis. <i>Journal of Psychiatric Research</i> , 2015 , 64, 88-98	5.2	39

494	Persistent benefits of slow titration of paroxetine in a six-month follow-up. <i>Human Psychopharmacology</i> , 2015 , 30, 329-33	2.3	1
493	P.1.a.002 Genetics of long-term treatment outcome in bipolar disorder. <i>European Neuropsychopharmacology</i> , 2015 , 25, S159-S160	1.2	
492	P.1.a.007 Four polymorphisms of SLC6A4 are novel predictors of SSRI/SNRI response in depressive disorder: sequencing analysis of SLC6A4. <i>European Neuropsychopharmacology</i> , 2015 , 25, S162-S163	1.2	1
491	Neuroticism, social network, stressful life events: association with mood disorders, depressive symptoms and suicidal ideation in a community sample of women. <i>Psychiatry Research</i> , 2015 , 226, 38-44	9.9	24
490	Association study of CREB1 polymorphisms and suicidality in MDD: results from a European multicenter study on treatment resistant depression. <i>International Journal of Neuroscience</i> , 2015 , 125, 336-43	2	7
489	A molecular pathway analysis of the glutamatergic-monoaminergic interplay serves to investigate the number of depressive records during citalopram treatment. <i>Journal of Neural Transmission</i> , 2015 , 122, 465-75	4.3	3
488	P1.a.023 Impact of a SNP in SIGMAR1 on major depression, bipolar disorder and treatment response. <i>European Neuropsychopharmacology</i> , 2015 , 25, S170-S171	1.2	
487	P.1.a.034 Genetic susceptibility to behavioural and psychological symptoms in Alzheimer disease: a systematic review. <i>European Neuropsychopharmacology</i> , 2015 , 25, S175-S176	1.2	
486	Serotonin 7 Receptor Variants Are Not Associated with Response to Second-Generation Antipsychotics in Japanese Schizophrenia Patients. <i>Neuropsychobiology</i> , 2015 , 72, 118-25	4	6
485	Alcohol Dependence and Genetic Variability in the Serotonin Pathway among Currently and Formerly Alcohol-Dependent Males. <i>Neuropsychobiology</i> , 2015 , 72, 57-64	4	9
484	Low-activity alleles of the MAOA gene are associated with measures of hostility. <i>Psychiatric Genetics</i> , 2015 , 25, 215	2.9	1
483	Genetics of second-generation antipsychotic and mood stabilizer-induced weight gain in bipolar disorder: common and specific effects of key regulators of fat-mass homeostasis genes. <i>Pharmacogenetics and Genomics</i> , 2015 , 25, 354-62	1.9	14
482	CACNA1C gene and schizophrenia: a case-control and pharmacogenetic study. <i>Psychiatric Genetics</i> , 2015 , 25, 163-7	2.9	19
481	HTR1A Gene Polymorphisms and 5-HT1A Receptor Partial Agonist Antipsychotics Efficacy in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2015 , 35, 220-7	1.7	17
480	Insomnia and somnolence associated with second-generation antidepressants during the treatment of major depression: a meta-analysis. <i>Journal of Clinical Psychopharmacology</i> , 2015 , 35, 296-303	1.7	34
479	Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications. <i>Current Psychiatry Reports</i> , 2015 , 17, 50	9.1	55
478	Temperament and character profiles in bipolar I, bipolar II and major depressive disorder: Impact over illness course, comorbidity pattern and psychopathological features of depression. <i>Journal of Affective Disorders</i> , 2015 , 184, 51-9	6.6	30
477	Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review. <i>American Journal of Psychiatry</i> , 2015 , 172, 617-29	11.9	111

476	P.1.a.006 CACNA1C gene and schizophrenia: A case-control and pharmacogenetic study. <i>European Neuropsychopharmacology</i> , 2015 , 25, S162	1.2	1
475	Schizophrenia-like symptoms in narcolepsy type 1: shared and distinctive clinical characteristics. <i>Neuropsychobiology</i> , 2015 , 71, 218-24	4	25
474	Cognitive markers of psychotic unipolar depression: a meta-analytic study. <i>Journal of Affective Disorders</i> , 2015 , 174, 580-8	6.6	40
473	Genetics of psychotropic medication induced side effects in two independent samples of bipolar patients. <i>Journal of Neural Transmission</i> , 2015 , 122, 43-58	4.3	10
472	The combined effect of genetic polymorphisms and clinical parameters on treatment outcome in treatment-resistant depression. <i>European Neuropsychopharmacology</i> , 2015 , 25, 441-53	1.2	58
471	A molecular pathway analysis informs the genetic background at risk for schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2015 , 59, 21-30	5.5	14
470	Genetic variability in CYP2E1 and catalase gene among currently and formerly alcohol-dependent male subjects. <i>Alcohol and Alcoholism</i> , 2015 , 50, 140-5	3.5	19
469	CRY1 Variations Impacts on the Depressive Relapse Rate in a Sample of Bipolar Patients. <i>Psychiatry Investigation</i> , 2015 , 12, 118-24	3.1	8
468	Dimensions of Delusions in Major Depression: Socio-demographic and Clinical Correlates in an Unipolar-Bipolar Sample. <i>Clinical Psychopharmacology and Neuroscience</i> , 2015 , 13, 48-52	3.4	11
467	Family history of a mood disorder indicates a more severe bipolar disorder. <i>Journal of Affective Disorders</i> , 2014 , 156, 178-86	6.6	24
466	P.3.d.026 Pharmacogenetics of clozapine response and metabolic side effects: a comprehensive review and meta-analysis. <i>European Neuropsychopharmacology</i> , 2014 , 24, S536-S537	1.2	
465	Are mindfulness-based interventions effective for substance use disorders? A systematic review of the evidence. <i>Substance Use and Misuse</i> , 2014 , 49, 492-512	2.2	214
464	Serotonin transporter gene: a new polymorphism may affect response to antidepressant treatments in major depressive disorder. <i>Molecular Diagnosis and Therapy</i> , 2014 , 18, 567-77	4.5	14
463	DISC1-TSNAX and DAOA genes in major depression and citalopram efficacy. <i>Journal of Affective Disorders</i> , 2014 , 168, 91-7	6.6	11
462	Influence of differentially expressed genes from suicide post-mortem study on personality traits as endophenotypes on healthy subjects and suicide attempters. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2014 , 264, 423-32	5.1	10
461	Effects of antipsychotic drugs on insight in schizophrenia. <i>Psychiatry Research</i> , 2014 , 218, 20-4	9.9	10
460	Understanding the pharmacogenetics of selective serotonin reuptake inhibitors. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014 , 10, 1093-118	5.5	12
459	PPP3CC gene: a putative modulator of antidepressant response through the B-cell receptor signaling pathway. <i>Pharmacogenomics Journal</i> , 2014 , 14, 463-72	3.5	31

458	Lack of influence of rs4680 (COMT) and rs6276 (DRD2) on diagnosis and clinical outcomes in patients with major depression. <i>International Journal of Psychiatry in Clinical Practice</i> , 2014 , 18, 97-102	2.4	14
457	P.6.b.002 Oxidative stress and expression of alcohol related psychopathological symptoms in alcohol dependent subjects. <i>European Neuropsychopharmacology</i> , 2014 , 24, S664	1.2	
456	Modulation of a number of genes on personality traits in a sample of healthy subjects. <i>Neuroscience Letters</i> , 2014 , 566, 320-5	3.3	5
455	HSP70 polymorphisms in first psychotic episode drug-naïve schizophrenic patients. <i>Life Sciences</i> , 2014 , 100, 133-137	6.8	11
454	Family history of major depression and residual symptoms in responder and non-responder depressed patients. <i>Comprehensive Psychiatry</i> , 2014 , 55, 51-5	7.3	4
453	P.3.018 Insomnia and somnolence induced by second-generation antidepressants during the treatment of major depression: a meta-analysis. <i>European Neuropsychopharmacology</i> , 2014 , 24, S69-S70	1.2	
452	Role of synaptosome-related (SNARE) genes in adults with attention deficit hyperactivity disorder. <i>Psychiatry Research</i> , 2014 , 215, 799-800	9.9	8
451	The potential role of atypical antipsychotics for the treatment of posttraumatic stress disorder. <i>Journal of Psychiatric Research</i> , 2014 , 56, 72-81	5.2	20
450	From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment. <i>Canadian Journal of Psychiatry</i> , 2014 , 59, 62-75	4.8	37
449	Highlights from the latest articles in suicide research. <i>Personalized Medicine</i> , 2014 , 11, 255-258	2.2	
448	Trait-aggressiveness and impulsivity: role of psychological resilience and childhood trauma in a sample of male prisoners. <i>Nordic Journal of Psychiatry</i> , 2014 , 68, 8-17	2.3	17
447	Benefit of slow titration of paroxetine to treat depression in the elderly. <i>Human Psychopharmacology</i> , 2014 , 29, 544-51	2.3	4
446	Pharmacogenetics of Antidepressant Drugs 2014 , 543-562		
445	Serious suicidal behaviors: socio-demographic and clinical features in a multinational, multicenter sample. <i>Nordic Journal of Psychiatry</i> , 2014 , 68, 44-52	2.3	14
444	Clozapine augmentation with amisulpride. <i>Journal of Psychiatry and Neuroscience</i> , 2014 , 39, E38-9	4.5	5
443	The genetics of vascular incidents associated with second-generation antipsychotic administration. <i>Expert Review of Clinical Pharmacology</i> , 2014 , 7, 75-90	3.8	
442	Genes involved in neuroplasticity and stressful life events act on the short-term response to antidepressant treatment: a complex interplay between genetics and environment. <i>Human Psychopharmacology</i> , 2014 , 29, 388-91	2.3	11
441	Genetic variations within metalloproteinases impact on the prophylaxis of depressive phases in bipolar patients. <i>Neuropsychobiology</i> , 2014 , 69, 76-82	4	4

440	Genome-wide association study supports the role of the immunological system and of the neurodevelopmental processes in response to haloperidol treatment. <i>Pharmacogenetics and Genomics</i> , 2014 , 24, 314-9	1.9	24
439	Psychological mechanisms of mindfulness-based interventions: what do we know?. <i>Holistic Nursing Practice</i> , 2014 , 28, 124-48	1.2	69
438	Genetic modulation of personality traits: a systematic review of the literature. <i>International Clinical Psychopharmacology</i> , 2014 , 29, 1-15	2.2	57
437	Quetiapine extended release: preliminary evidence of a rapid onset of the antidepressant effect in bipolar depression. <i>Journal of Clinical Psychopharmacology</i> , 2014 , 34, 303-6	1.7	4
436	Specificity profile of venlafaxine and sertraline in major depression: metaregression of double-blind, randomized clinical trials. <i>International Journal of Neuropsychopharmacology</i> , 2014 , 17, 1-8	5.8	23
435	Genomewide interaction and enrichment analysis on antidepressant response. <i>Psychological Medicine</i> , 2014 , 44, 753-65	6.9	5
434	The association of personality trait on treatment outcomes in patients with chronic prostatitis/chronic pelvic pain syndrome: an exploratory study. <i>Journal of Psychosomatic Research</i> , 2014 , 76, 127-33	4.1	18
433	The neuropsychological hypothesis of antidepressant drug action revisited. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014 , 13, 1722-39	2.6	2
432	Abelson helper integration site-1 gene variants on major depressive disorder and bipolar disorder. <i>Psychiatry Investigation</i> , 2014 , 11, 481-6	3.1	9
431	Epistatic Interactions between CREB and CREM Variants in Affective Disorder. <i>Psychiatry Investigation</i> , 2014 , 11, 200-3	3.1	1
430	Mixed, melancholic, and anxious features in depression: a cross-sectional study of sociodemographic and clinical correlates. <i>Annals of Clinical Psychiatry</i> , 2014 , 26, 243-53	1.4	4
429	Screening genetic variability at the CNR1 gene in both major depression etiology and clinical response to citalopram treatment. <i>Psychopharmacology</i> , 2013 , 227, 509-19	4.7	40
428	Evaluation of the role of MAPK1 and CREB1 polymorphisms on treatment resistance, response and remission in mood disorder patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013 , 44, 271-8	5.5	35
427	Gene environment interaction studies in depression and suicidal behavior: An update. <i>Neuroscience and Biobehavioral Reviews</i> , 2013 , 37, 2375-97	9	124
426	MAOA and MAOB polymorphisms and anger-related traits in suicidal participants and controls. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013 , 263, 393-403	5.1	22
425	Influence of family history of major depression, bipolar disorder, and suicide on clinical features in patients with major depression and bipolar disorder. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013 , 263, 93-103	5.1	20
424	The serotonin 1A receptor gene confer susceptibility to mood disorders: results from an extended meta-analysis of patients with major depression and bipolar disorder. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013 , 263, 105-18	5.1	76
423	Association between Sirtuin 2 gene rs10410544 polymorphism and depression in Alzheimer's disease in two independent European samples. <i>Journal of Neural Transmission</i> , 2013 , 120, 1709-15	4.3	26

422	Serotonergic genes and suicide: a systematic review. <i>European Neuropsychopharmacology</i> , 2013 , 23, 1125-42	9.1	91
421	Variation in the HTR1A and HTR2A genes and social adjustment in depressed patients. <i>Journal of Affective Disorders</i> , 2013 , 150, 649-52	6.6	9
420	Case-control association study of 36 single-nucleotide polymorphisms within 10 candidate genes for major depression and bipolar disorder. <i>Psychiatry Research</i> , 2013 , 209, 121-3	9.9	19
419	The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. <i>American Journal of Psychiatry</i> , 2013 , 170, 1249-62	11.9	451
418	Genetic modulation of borderline personality disorder: systematic review and meta-analysis. <i>Journal of Psychiatric Research</i> , 2013 , 47, 1275-87	5.2	36
417	Mindfulness: top-down or bottom-up emotion regulation strategy?. <i>Clinical Psychology Review</i> , 2013 , 33, 82-96	10.8	247
416	Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2013 , 162B, 487-520	3.5	66
415	The 5-HTTLPR polymorphism and posttraumatic stress disorder: a meta-analysis. <i>Journal of Traumatic Stress</i> , 2013 , 26, 645-53	3.8	74
414	The role of COMT gene variants in depression: Bridging neuropsychological, behavioral and clinical phenotypes. <i>Neuroscience and Biobehavioral Reviews</i> , 2013 , 37, 1597-610	9	75
413	Temperamental and genetic predictors of suicide attempt and self-mutilation. <i>Neuropsychobiology</i> , 2013 , 68, 250-7	4	5
412	Clinical, psychological and environmental predictors of prospective suicide events in patients with Bipolar Disorder. <i>Journal of Psychiatric Research</i> , 2013 , 47, 1800-8	5.2	37
411	Investigation of epistasis between DAOA and 5HTR1A variants on clinical outcomes in patients with schizophrenia. <i>Genetic Testing and Molecular Biomarkers</i> , 2013 , 17, 504-7	1.6	8
410	Diagnostic accuracy of serum brain derived neurotrophic factor concentration in antidepressant naïve patients with first major depression episode. <i>Journal of Psychiatric Research</i> , 2013 , 47, 162-7	5.2	21
409	Treatment strategies according to clinical features in a naturalistic cohort study of bipolar patients: a principal component analysis of lifetime pharmacological and biophysics treatment options. <i>European Neuropsychopharmacology</i> , 2013 , 23, 263-75	1.2	23
408	Influence of ANKK1 and DRD2 polymorphisms in response to haloperidol. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013 , 263, 65-74	5.1	15
407	Challenging sequential approach to treatment resistant depression: cost-utility analysis based on the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial. <i>European Neuropsychopharmacology</i> , 2013 , 23, 1739-46	1.2	8
406	P.5.b.002 Association between sirtuin 2 gene rs10410544 polymorphism and depression in Alzheimer's disease in two independent European samples. <i>European Neuropsychopharmacology</i> , 2013 , 23, S540-S541	1.2	
405	Physical co-morbidity among treatment resistant vs. treatment responsive patients with major depressive disorder. <i>European Neuropsychopharmacology</i> , 2013 , 23, 895-901	1.2	20

404	Early antidepressant efficacy modulation by glutamatergic gene variants in the STAR*D. <i>European Neuropsychopharmacology</i> , 2013 , 23, 612-21	1.2	22
403	AKAP13, CACNA1, GRIK4 and GRIA1 genetic variations may be associated with haloperidol efficacy during acute treatment. <i>European Neuropsychopharmacology</i> , 2013 , 23, 887-94	1.2	26
402	Clinical features and drug induced side effects in early versus late antidepressant responders. <i>Journal of Psychiatric Research</i> , 2013 , 47, 1309-18	5.2	24
401	Antidepressants in elderly: metaregression of double-blind, randomized clinical trials. <i>Journal of Affective Disorders</i> , 2013 , 147, 1-8	6.6	63
400	P.1.a.016 CHL1 gene: a new promising antidepressant response marker in major depression. <i>European Neuropsychopharmacology</i> , 2013 , 23, S168-S169	1.2	
399	P.2.f.025 Specificity profile of venlafaxine and sertraline in major depression: meta-regression of double-blind, randomized clinical trials. <i>European Neuropsychopharmacology</i> , 2013 , 23, S409-S410	1.2	
398	Authors' reply to "Recommendations for conducting mindfulness based cognitive therapy trials". <i>Psychiatry Research</i> , 2013 , 207, 232-3	9.9	
397	Social adjustment among treatment responder patients with mood disorders. <i>Journal of Affective Disorders</i> , 2013 , 150, 961-6	6.6	2
396	The impact of Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes on suicide attempt and suicide risk-a European multicentre study on treatment-resistant major depressive disorder. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013 , 263, 385-91	5.1	12
395	Genetics of Treatment-resistant Depression 2013 , 43-90		1
394	Shared genetics among major psychiatric disorders. <i>Lancet, The</i> , 2013 , 381, 1339-1341	4.0	38
393	Potential role of membrane-bound COMT gene polymorphisms in female depression vulnerability. <i>Journal of Affective Disorders</i> , 2013 , 148, 316-22	6.6	15
392	Pharmacogenetics in major depression: a comprehensive meta-analysis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013 , 45, 183-94	5.5	148
391	Side effects associated with psychotropic medications in patients with bipolar disorder: evidence from two independent samples. <i>Journal of Psychopharmacology</i> , 2013 , 27, 616-28	4.6	17
390	Impact of 5-HTTLPR polymorphism on alexithymia in alcoholic patients after detoxification treatment. <i>Journal of Addiction Medicine</i> , 2013 , 7, 372-3	3.8	3
389	Investigation of possible epistatic interactions between GRIA2 and GRIA4 variants on clinical outcomes in patients with major depressive disorder. <i>Journal of International Medical Research</i> , 2013 , 41, 809-15	1.4	6
388	TPH1, MAOA, serotonin receptor 2A and 2C genes in citalopram response: possible effect in melancholic and psychotic depression. <i>Neuropsychobiology</i> , 2013 , 67, 41-7	4	25
387	Newer antidepressants and panic disorder: a meta-analysis. <i>International Clinical Psychopharmacology</i> , 2013 , 28, 33-45	2.2	37

386	The impact of adverse life events on clinical features and interaction with gene variants in mood disorder patients. <i>Psychopathology</i> , 2013 , 46, 384-9	3.4	9
385	A Genetic Dissection of Antipsychotic Induced Movement Disorders. <i>Current Medicinal Chemistry</i> , 2013 , 20, 312-330	4.3	7
384	5-HTTLPR rs25531A > G differentially influence paroxetine and fluvoxamine antidepressant efficacy: a randomized, controlled trial. <i>Journal of Clinical Psychopharmacology</i> , 2013 , 33, 131-2	1.7	11
383	Potential benefits of slow titration of paroxetine treatment in an elderly population: eight-week results from a naturalistic setting. <i>Journal of Clinical Psychopharmacology</i> , 2013 , 33, 565-9	1.7	2
382	Genetics of serotonin receptors and depression: state of the art. <i>Current Drug Targets</i> , 2013 , 14, 531-48	3	22
381	Effects of SORL1 gene on Alzheimer's disease. Focus on gender, neuropsychiatric symptoms and pro-inflammatory cytokines. <i>Current Alzheimer Research</i> , 2013 , 10, 154-64	3	10
380	No effect of serotoninergic gene variants on response to interpersonal counseling and antidepressants in major depression. <i>Psychiatry Investigation</i> , 2013 , 10, 180-9	3.1	18
379	A genetic dissection of antipsychotic induced movement disorders. <i>Current Medicinal Chemistry</i> , 2013 , 20, 312-30	4.3	6
378	Treatment resistance in severe unipolar depression: no association with psychotic or melancholic features. <i>Annals of Clinical Psychiatry</i> , 2013 , 25, 97-106	1.4	5
377	P.2.a.011 Treatment strategies according to clinical features in a naturalistic cohort study of bipolar patients. <i>European Neuropsychopharmacology</i> , 2012 , 22, S230	1.2	
376	P.3.c.044 Influence of ANKK1 and DRD2 gene polymorphisms in response to haloperidol. <i>European Neuropsychopharmacology</i> , 2012 , 22, S342	1.2	
375	Clozapine resistance: augmentation strategies. <i>European Neuropsychopharmacology</i> , 2012 , 22, 165-82	1.2	99
374	The impact of COMT gene polymorphisms on suicidality in treatment resistant major depressive disorder--a European multicenter study. <i>European Neuropsychopharmacology</i> , 2012 , 22, 259-66	1.2	32
373	Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. <i>European Neuropsychopharmacology</i> , 2012 , 22, 239-58	1.2	238
372	European Group for the Study of Resistant Depression (GSRD)--where have we gone so far: review of clinical and genetic findings. <i>European Neuropsychopharmacology</i> , 2012 , 22, 453-68	1.2	91
371	Case-control association study of 14 variants of CREB1, CREBBP and CREM on diagnosis and treatment outcome in major depressive disorder and bipolar disorder. <i>Psychiatry Research</i> , 2012 , 198, 39-46	9.9	18
370	Serum concentrations of CRP, IL-6, TNF- α and cortisol in major depressive disorder with melancholic or atypical features. <i>Psychiatry Research</i> , 2012 , 198, 74-80	9.9	113
369	Prolactin and thyroid hormone levels are associated with suicide attempts in psychiatric patients. <i>Psychiatry Research</i> , 2012 , 200, 389-94	9.9	79

368	Increased inflammation and lower platelet 5-HT in depression with metabolic syndrome. <i>Journal of Affective Disorders</i> , 2012 , 141, 72-8	6.6	18
367	Case-control association study of GRIA1, GRIA2 and GRIA4 polymorphisms in bipolar disorder. <i>International Journal of Psychiatry in Clinical Practice</i> , 2012 , 16, 18-26	2.4	6
366	DAOA variants on diagnosis and response to treatment in patients with major depressive disorder and bipolar disorder. <i>Journal of International Medical Research</i> , 2012 , 40, 258-65	1.4	5
365	Should pharmacogenetics be incorporated in major depression treatment? Economic evaluation in high- and middle-income European countries. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012 , 36, 147-54	5.5	27
364	Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to antipsychotic treatment in patients with schizophrenia. <i>Neuroscience Letters</i> , 2012 , 506, 170-4	3.3	14
363	Possible influence of CREB1, CREBBP and CREM variants on diagnosis and treatment outcome in patients with schizophrenia. <i>Neuroscience Letters</i> , 2012 , 508, 37-41	3.3	9
362	Influence of COX-2 and OXTR polymorphisms on treatment outcome in treatment resistant depression. <i>Neuroscience Letters</i> , 2012 , 516, 85-8	3.3	21
361	Generalized tonic-clonic seizure secondary to duloxetine poisoning: a short report with favorable out come. <i>NeuroToxicology</i> , 2012 , 33, 189-90	4.4	9
360	Depression across mood disorders: review and analysis in a clinical sample. <i>Comprehensive Psychiatry</i> , 2012 , 53, 24-38	7.3	28
359	Pharmacogenetics of antidepressants and mood stabilizers. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2012 , 106, 715-44	3	8
358	The 3111T/C polymorphism interacts with stressful life events to influence patterns of sleep in females. <i>Chronobiology International</i> , 2012 , 29, 891-7	3.6	24
357	Influence of BDNF variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia. <i>Neuropsychobiology</i> , 2012 , 65, 1-11	4	46
356	The role of serotonergic genes and environmental stress on the development of depressive symptoms and neuroticism. <i>Journal of Affective Disorders</i> , 2012 , 142, 82-9	6.6	27
355	Paroxetine for the treatment of depression: a critical update. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 421-31	4	84
354	Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to treatment in patients with major depressive disorder. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012 , 262, 305-11	5.1	23
353	Case-control association study for 10 genes in patients with schizophrenia: influence of 5HTR1A variation rs10042486 on schizophrenia and response to antipsychotics. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012 , 262, 199-205	5.1	29
352	Bipolar disorder: "pure" versus mixed depression over a 1-year follow-up. <i>International Journal of Psychiatry in Clinical Practice</i> , 2012 , 16, 113-20	2.4	6
351	Quetiapine for bipolar depression: a systematic review and meta-analysis. <i>International Clinical Psychopharmacology</i> , 2012 , 27, 76-90	2.2	36

350	Mindfulness-based cognitive therapy versus psycho-education for patients with major depression who did not achieve remission following antidepressant treatment: a preliminary analysis. <i>Journal of Alternative and Complementary Medicine</i> , 2012 , 18, 756-60	2.4	46
349	Failure to replicate influence of GRIK4 and GNB3 polymorphisms on treatment outcome in major depression. <i>Neuropsychobiology</i> , 2012 , 65, 70-5	4	20
348	Role of substance abuse comorbidity and personality on the outcome of depression in bipolar disorder: harm avoidance influences medium-term treatment outcome. <i>Psychopathology</i> , 2012 , 45, 174-8	3.4	17
347	Antipsychotic response in the first week predicts later efficacy. <i>Neuropsychobiology</i> , 2012 , 66, 100-5	4	10
346	Association of SORL1 alleles with late-onset Alzheimer's disease. findings from the GIGAS_LOAD study and mega-analysis. <i>Current Alzheimer Research</i> , 2012 , 9, 491-9	3	11
345	Catechol-o-methyltransferase and Alzheimer's disease: a review of biological and genetic findings. <i>CNS and Neurological Disorders - Drug Targets</i> , 2012 , 11, 299-305	2.6	21
344	Serum testosterone concentration in combat-related chronic posttraumatic stress disorder. <i>Neuropsychobiology</i> , 2012 , 65, 90-5	4	17
343	No association of a set of candidate genes on haloperidol side effects. <i>PLoS ONE</i> , 2012 , 7, e44853	3.7	7
342	FC04-06 - Candidate gene association study of suicidality in treatment resistant MDD. <i>European Psychiatry</i> , 2011 , 26, 1833-1833	6	
341	Clock genes and mood disorders: Which role?. <i>European Psychiatry</i> , 2011 , 26, 2136-2136	6	
340	Mindfulness-based interventions for chronic pain: a systematic review of the evidence. <i>Journal of Alternative and Complementary Medicine</i> , 2011 , 17, 83-93	2.4	220
339	Clinical and demographic predictors of improvement during duloxetine treatment in patients with major depression: an open-label study. <i>Clinical Drug Investigation</i> , 2011 , 31, 385-405	3.2	8
338	Genetics of late-onset Alzheimer's disease: update from the alzne database and analysis of shared pathways. <i>International Journal of Alzheimer's Disease</i> , 2011 , 2011, 832379	3.7	36
337	Novel antidepressants and panic disorder: evidence beyond current guidelines. <i>Neuropsychobiology</i> , 2011 , 63, 1-7	4	11
336	The CLOCK gene and mood disorders: a case-control study and meta-analysis. <i>Chronobiology International</i> , 2011 , 28, 825-33	3.6	33
335	Does mindfulness training improve cognitive abilities? A systematic review of neuropsychological findings. <i>Clinical Psychology Review</i> , 2011 , 31, 449-64	10.8	720
334	COMT and age at onset in mood disorders: a replication and extension study. <i>Neuroscience Letters</i> , 2011 , 498, 218-21	3.3	27
333	The molecular interaction between the glutamatergic, noradrenergic, dopaminergic and serotonergic systems informs a detailed genetic perspective on depressive phenotypes. <i>Progress in Neurobiology</i> , 2011 , 94, 418-60	10.9	54

332	Sociodemographic and treatment related variables are poor predictors of haloperidol induced motor side effects. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011 , 35, 74-7	5.5	6
331	Mechanisms of antidepressant action: an integrated dopaminergic perspective. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011 , 35, 1532-43	5.5	30
330	Mindfulness based cognitive therapy for psychiatric disorders: a systematic review and meta-analysis. <i>Psychiatry Research</i> , 2011 , 187, 441-53	9.9	436
329	No influence of PTGS2 polymorphisms on response and remission to antidepressants in major depression. <i>Psychiatry Research</i> , 2011 , 188, 166-9	9.9	9
328	Influence of TPH2 variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia. <i>Psychiatry Research</i> , 2011 , 189, 26-32	9.9	38
327	The genetics of antipsychotic induced tremors: a genome-wide pathway analysis on the STEP-BD SCP sample. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2011 , 156B, 975-86	3.5	19
326	E.02.02 Pitfalls, problems and future. <i>European Neuropsychopharmacology</i> , 2011 , 21, S233-S234	1.2	
325	P.2.c.026 Rapid versus slow titration of paroxetine antidepressant treatment in elderly population: an observational study. <i>European Neuropsychopharmacology</i> , 2011 , 21, S397-S398	1.2	
324	P.2.e.025 Bipolar depression: quetiapine extended release effectiveness. <i>European Neuropsychopharmacology</i> , 2011 , 21, S432	1.2	
323	P.3.c.055 Clozapine resistance: augmentation strategies. <i>European Neuropsychopharmacology</i> , 2011 , 21, S500	1.2	2
322	A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders. <i>World Journal of Biological Psychiatry</i> , 2011 , 12, 501-15	3.8	29
321	Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011 , 7, 1101-15	5.5	59
320	A protective genetic variant for adverse environments? The role of childhood traumas and serotonin transporter gene on resilience and depressive severity in a high-risk population. <i>European Psychiatry</i> , 2011 , 26, 471-8	6	36
319	Sociodemographic features predict antidepressant trajectories of response in diverse antidepressant pharmacotreatment environments: a comparison between the STAR*D study and an independent trial. <i>Journal of Clinical Psychopharmacology</i> , 2011 , 31, 345-8	1.7	9
318	A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. <i>International Clinical Psychopharmacology</i> , 2011 , 26, 130-40	2.2	106
317	Switching antidepressant class does not improve response or remission in treatment-resistant depression. <i>Journal of Clinical Psychopharmacology</i> , 2011 , 31, 512-6	1.7	71
316	Self-harm in prisoners. <i>CNS Spectrums</i> , 2011 , 16, 75-81	1.8	15
315	Pharmacogenetics of antidepressants. <i>Frontiers in Pharmacology</i> , 2011 , 2, 6	5.6	55

314	Serotonin transporter gene variants and prediction of stress-induced risk for psychological distress. <i>Genes, Brain and Behavior</i> , 2011 , 10, 536-41	3.6	5
313	Is cognitive behavioural therapy an effective complement to antidepressants in adolescents? A meta-analysis. <i>Acta Neuropsychiatrica</i> , 2011 , 23, 263-271	3.9	13
312	Sexual side effects of pharmacological treatment of psychiatric diseases. <i>Clinical Pharmacology and Therapeutics</i> , 2011 , 89, 142-7	6.1	62
311	Catechol-o-methyltransferase gene modulation on suicidal behavior and personality traits: review, meta-analysis and association study. <i>Journal of Psychiatric Research</i> , 2011 , 45, 309-21	5.2	112
310	The influence of childhood trauma on the onset and repetition of suicidal behavior: an investigation in a high risk sample of male prisoners. <i>Journal of Psychiatric Research</i> , 2011 , 45, 742-7	5.2	53
309	A preliminary investigation of the influence of CREB1 gene on treatment resistance in major depression. <i>Journal of Affective Disorders</i> , 2011 , 128, 56-63	6.6	43
308	Specificity profile of paroxetine in major depressive disorder: meta-regression of double-blind, randomized clinical trials. <i>Journal of Affective Disorders</i> , 2011 , 132, 14-25	6.6	22
307	Phenomenology of psychotic mood disorders: lifetime and major depressive episode features. <i>Journal of Affective Disorders</i> , 2011 , 135, 241-50	6.6	21
306	Lack of association between 71 variations located in candidate genes and response to acute haloperidol treatment. <i>Psychopharmacology</i> , 2011 , 214, 719-28	4.7	2
305	The 5-HTTLPR polymorphism and eating disorders: a meta-analysis. <i>International Journal of Eating Disorders</i> , 2011 , 44, 191-9	6.3	61
304	DAOA variants and schizophrenia: influence on diagnosis and treatment outcomes. <i>International Journal of Psychiatry in Clinical Practice</i> , 2011 , 15, 303-10	2.4	4
303	Citalopram versus desipramine in treatment resistant depression: effect of continuation or switching strategies: a randomized open study. <i>World Journal of Biological Psychiatry</i> , 2011 , 12, 364-75	3.8	34
302	NCAM1, TACR1 and NOS genes and temperament: a study on suicide attempters and controls. <i>Neuropsychobiology</i> , 2011 , 64, 32-7	4	10
301	Safety and tolerability of lamotrigine: results from 12 placebo-controlled clinical trials and clinical implications. <i>Clinical Neuropharmacology</i> , 2011 , 34, 39-47	1.4	40
300	Neuro-imaging of mindfulness meditations: implications for clinical practice. <i>Epidemiology and Psychiatric Sciences</i> , 2011 , 20, 205-10	5.1	15
299	Factors associated with the course of symptoms in bipolar disorder during a 1-year follow-up: depression vs. sub-threshold mixed state. <i>Nordic Journal of Psychiatry</i> , 2011 , 65, 419-26	2.3	10
298	Pharmacogenetics of antidepressant response. <i>Journal of Psychiatry and Neuroscience</i> , 2011 , 36, 87-113	4.5	112
297	Glutamatergic gene variants impact the clinical profile of efficacy and side effects of haloperidol. <i>Pharmacogenetics and Genomics</i> , 2011 , 21, 206-16	1.9	21

296	Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. <i>Molecular Psychiatry</i> , 2010 , 15, 473-500	15.1	354
295	Functional neural correlates of mindfulness meditations in comparison with psychotherapy, pharmacotherapy and placebo effect. Is there a link?. <i>Acta Neuropsychiatrica</i> , 2010 , 22, 104-17	3.9	31
294	Pharmacogenomics of Depression. <i>Advances in Biological Psychiatry</i> , 2010 , 58-74		1
293	Pharmacogenetics of lithium long-term treatment: focus on initiation and adaptation mechanisms. <i>Neuropsychobiology</i> , 2010 , 62, 61-71	4	10
292	Weight gain in antipsychotic-naïve patients: a review and meta-analysis. <i>Psychological Medicine</i> , 2010 , 40, 187-200	6.9	81
291	No influence of DTNBP1 polymorphisms on the response to aripiprazole. <i>Neuropsychobiology</i> , 2010 , 62, 245-9	4	3
290	No influence of SLC6A3 40 base VNTR polymorphism on the response to risperidone. <i>International Journal of Psychiatry in Clinical Practice</i> , 2010 , 14, 228-32	2.4	1
289	T3111C clock single nucleotide polymorphism and mood disorders: a meta-analysis. <i>Chronobiology International</i> , 2010 , 27, 706-21	3.6	22
288	Analysis of requirements and specifications for a monitoring system to support the self-management of dementia patients at home 2010 ,		2
287	No influence of FAT polymorphisms in response to aripiprazole. <i>Journal of Human Genetics</i> , 2010 , 55, 32-6	4.3	5
286	A systematic review of neurobiological and clinical features of mindfulness meditations. <i>Psychological Medicine</i> , 2010 , 40, 1239-52	6.9	440
285	Predictors of early worsening after switch to aripiprazole: a randomized, controlled, open-label study. <i>Clinical Drug Investigation</i> , 2010 , 30, 187-93	3.2	9
284	MDR1 gene polymorphisms and response to acute risperidone treatment. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010 , 34, 387-92	5.5	28
283	Quetiapine XR: current status for the treatment of major depressive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010 , 34, 1165-73	5.5	37
282	Influence of neuronal cell adhesion molecule (NCAM1) variants on suicidal behaviour and correlated traits. <i>Psychiatry Research</i> , 2010 , 179, 222-5	9.9	8
281	TAAR6 variations possibly associated with antidepressant response and suicidal behavior. <i>Psychiatry Research</i> , 2010 , 180, 20-4	9.9	14
280	Excessive daytime sleepiness in depressed women. <i>Psychiatry Research</i> , 2010 , 179, 171-5	9.9	6
279	Further evidence supporting the association between 5HT2C gene and bipolar disorder. <i>Psychiatry Research</i> , 2010 , 180, 151-2	9.9	6

278	Influence of DAOA gene variants on antipsychotic response after switch to aripiprazole. <i>Psychiatry Research</i> , 2010 , 178, 430-2	9.9	9
277	Antidepressants in healthy subjects: what are the psychotropic/psychological effects?. <i>European Neuropsychopharmacology</i> , 2010 , 20, 433-53	1.2	44
276	3111T/C clock gene polymorphism is not associated with sleep disturbances in untreated depressed patients. <i>Chronobiology International</i> , 2010 , 27, 265-77	3.6	30
275	No association between genetic markers in BDNF gene and lithium prophylaxis in a Greek sample. <i>International Journal of Psychiatry in Clinical Practice</i> , 2010 , 14, 154-7	2.4	6
274	Further evidence supporting the influence of brain-derived neurotrophic factor on the outcome of bipolar depression: independent effect of brain-derived neurotrophic factor and harm avoidance. <i>Journal of Psychopharmacology</i> , 2010 , 24, 1747-54	4.6	15
273	Identification of clinical factors associated with resistance to antidepressants in bipolar depression: results from an European Multicentre Study. <i>International Clinical Psychopharmacology</i> , 2010 , 25, 297-301	2.2	12
272	Vitamin B12 levels in Alzheimer's disease: association with clinical features and cytokine production. <i>Journal of Alzheimer's Disease</i> , 2010 , 19, 481-8	4.3	27
271	The use of the defence style questionnaire in major depressive and panic disorders: a comprehensive meta-analysis. <i>Psychology and Psychotherapy: Theory, Research and Practice</i> , 2010 , 83, 1-13	3.5	29
270	HTR1B as a risk profile maker in psychiatric disorders: a review through motivation and memory. <i>European Journal of Clinical Pharmacology</i> , 2010 , 66, 5-27	2.8	26
269	Interaction of haloperidol plasma level and antipsychotic effect in early phases of acute psychosis treatment. <i>Journal of Psychiatric Research</i> , 2010 , 44, 487-92	5.2	21
268	Correlation of a set of gene variants, life events and personality features on adult ADHD severity. <i>Journal of Psychiatric Research</i> , 2010 , 44, 598-604	5.2	22
267	APOE epsilon-4 allele and cytokine production in Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2010 , 25, 338-44	3.9	24
266	Investigation of an epistatic effect between a set of TAAR6 and HSP-70 genes variations and major mood disorders. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2010 , 153B, 680-683	3.5	11
265	Antidepressants and body weight: a comprehensive review and meta-analysis. <i>Journal of Clinical Psychiatry</i> , 2010 , 71, 1259-72	4.6	356
264	Epistasis between IL1A, IL1B, TNF, HTR2A, 5-HTTLPR and TPH2 variations does not impact alcohol dependence disorder features. <i>International Journal of Environmental Research and Public Health</i> , 2009 , 6, 1980-90	4.6	10
263	Tyrosine hydroxylase and DOPA decarboxylase gene variants in personality traits. <i>Neuropsychobiology</i> , 2009 , 59, 23-7	4	6
262	The impact of heat shock protein 70 gene variations on clinical presentation and outcome in schizophrenic inpatients. <i>Neuropsychobiology</i> , 2009 , 59, 135-41	4	19
261	Lithium pharmacodynamics and pharmacogenetics: focus on inositol mono phosphatase (IMPase), inositol poliphosphatase (IPPase) and glycogen synthase kinase 3 beta (GSK-3 beta). <i>Current Medicinal Chemistry</i> , 2009 , 16, 1917-48	4.3	23

260	Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressants. <i>Expert Opinion on Pharmacotherapy</i> , 2009 , 10, 1561-70	4	43
259	Serotonin receptor HTR1A and HTR2C variants and personality traits in suicide attempters and controls. <i>Journal of Psychiatric Research</i> , 2009 , 43, 519-25	5.2	36
258	Personality and attempted suicide. Analysis of anger, aggression and impulsivity. <i>Journal of Psychiatric Research</i> , 2009 , 43, 1262-71	5.2	137
257	Clinical features, response to treatment and functional outcome of bipolar disorder patients with and without co-occurring substance use disorder: 1-year follow-up. <i>Journal of Affective Disorders</i> , 2009 , 115, 27-35	6.6	64
256	Depressive symptomatology is influenced by chronotypes. <i>Journal of Affective Disorders</i> , 2009 , 119, 100-6	6.6	152
255	Harm avoidance moderates the influence of serotonin transporter gene variants on treatment outcome in bipolar patients. <i>Journal of Affective Disorders</i> , 2009 , 119, 205-9	6.6	32
254	Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2009 , 150B, 115-23	3.5	79
253	Do the estrogen receptors 1 gene variants influence the temperament and character inventory scores in suicidal attempters and healthy subjects?. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2009 , 150B, 434-8	3.5	7
252	Focus on HTR2C: A possible suggestion for genetic studies of complex disorders. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2009 , 150B, 601-37	3.5	44
251	Dysbindin gene (DTNBP1) and schizophrenia in Korean population. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2009 , 259, 137-42	5.1	18
250	Schizophrenia: genetics, prevention and rehabilitation. <i>Acta Neuropsychiatrica</i> , 2009 , 21, 109-20	3.9	8
249	Thyroid hormones affect recovery from depression during antidepressant treatment. <i>Psychiatry and Clinical Neurosciences</i> , 2009 , 63, 305-13	6.2	14
248	Effectiveness of antidepressant treatments in pre-menopausal versus post-menopausal women: a pilot study on differential effects of sex hormones on antidepressant effects. <i>Biomedicine and Pharmacotherapy</i> , 2009 , 63, 228-35	7.5	59
247	TPH2 gene variants and anxiety during alcohol detoxification outcome. <i>Psychiatry Research</i> , 2009 , 167, 106-14	9.9	9
246	5-HT2A gene variants influence specific and different aspects of antidepressant response in Japanese and Italian mood disorder patients. <i>Psychiatry Research</i> , 2009 , 167, 97-105	9.9	23
245	Influence of TAAR6 polymorphisms on response to aripiprazole. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009 , 33, 822-6	5.5	6
244	TAAR 6 and HSP-70 variations associated with bipolar disorder. <i>Neuroscience Letters</i> , 2009 , 465, 257-61	3.3	11
243	Association between the estrogen receptor TA polymorphism and Harm avoidance. <i>Neuroscience Letters</i> , 2009 , 467, 155-8	3.3	14

242	Are Noradrenergic Antidepressants a Valuable Choice in the Treatment of Panic Disorder? A Review and Meta Analysis. <i>European Psychiatry</i> , 2009 , 24, 1-1	6	
241	Interaction between SERTPR and stressful life events on response to antidepressant treatment. <i>European Neuropsychopharmacology</i> , 2009 , 19, 64-7	1.2	40
240	Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study. <i>European Neuropsychopharmacology</i> , 2009 , 19, 562-70	1.2	40
239	Effect of basic fibroblast growth factor (FGF2) gene polymorphisms on SSRIs treatment response and side effects. <i>European Neuropsychopharmacology</i> , 2009 , 19, 718-25	1.2	16
238	Epistasis between a set of variations located in the TAAR6 and HSP-70 genes toward schizophrenia and response to antipsychotic treatment. <i>European Neuropsychopharmacology</i> , 2009 , 19, 806-11	1.2	7
237	The socio-economical burden of schizophrenia: a simulation of cost-offset of early intervention program in Italy. <i>European Psychiatry</i> , 2009 , 24, 11-6	6	21
236	Corrigendum to: "TAAR6 variation effect on clinic presentation and outcome in a sample of schizophrenic in-patients: An open label study"[<i>Eur Psychiatr</i> 2008;23:3908]. <i>European Psychiatry</i> , 2009 , 24, 64-64	6	
235	Mindfulness-based stress reduction for stress management in healthy people: a review and meta-analysis. <i>Journal of Alternative and Complementary Medicine</i> , 2009 , 15, 593-600	2.4	940
234	Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. <i>Journal of Clinical Psychopharmacology</i> , 2009 , 29, 259-66	1.7	353
233	Common genetic, clinical, demographic and psychosocial predictors of response to pharmacotherapy in mood and anxiety disorders. <i>International Clinical Psychopharmacology</i> , 2009 , 24, 1-18	2.2	39
232	Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients. <i>International Clinical Psychopharmacology</i> , 2009 , 24, 250-6	2.2	57
231	Dysbindin gene (DTNBP1) in major depression: association with clinical response to selective serotonin reuptake inhibitors. <i>Pharmacogenetics and Genomics</i> , 2009 , 19, 121-8	1.9	21
230	Lack of association between interleukin-1 alpha rs1800587 polymorphism and Alzheimer's disease in two Independent European samples. <i>Journal of Alzheimer's Disease</i> , 2009 , 16, 181-7	4.3	22
229	Pharmacogenetics of antidepressant response: an update. <i>Human Genomics</i> , 2009 , 3, 257-74	6.8	30
228	Genetics of Mood Disorders 2009 , 125-133		0
227	The genetics of bipolar disorder: genome 'hot regions,' genes, new potential candidates and future directions. <i>Molecular Psychiatry</i> , 2008 , 13, 742-71	15.1	151
226	Temperament and character of suicide attempters. <i>Journal of Psychiatric Research</i> , 2008 , 42, 938-45	5.2	56
225	DTNBP1 haplotype influences baseline assessment scores of schizophrenic in-patients. <i>Neuroscience Letters</i> , 2008 , 440, 150-4	3.3	14

224	Estrogen receptor gene 1 variants are not associated with suicidal behavior. <i>Psychiatry Research</i> , 2008 , 160, 1-7	9.9	13
223	Association between GSK-3beta -50T/C polymorphism and personality and psychotic symptoms in mood disorders. <i>Psychiatry Research</i> , 2008 , 158, 132-40	9.9	37
222	Metabolic side effects of second generation antipsychotic agents in antipsychotic-naïve patients: one-month prospective evaluation. <i>Psychiatry Research</i> , 2008 , 157, 269-71	9.9	7
221	Is there protective haplotype of dysbindin gene (DTNBP1) 3 polymorphisms for major depressive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008 , 32, 375-9	5.5	16
220	ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008 , 32, 398-404	5.5	112
219	Antidepressant response and intolerance to SSRI is not influenced by G-protein beta3 subunit gene C825T polymorphism in Japanese major depressive patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008 , 32, 1041-4	5.5	29
218	Acute antipsychotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008 , 32, 1562-6	5.5	39
217	Psychometric characteristic of the Italian version of the Temperament and Character Inventory--revised, personality, psychopathology, and attachment styles. <i>Comprehensive Psychiatry</i> , 2008 , 49, 514-22	7.3	67
216	P.1.a.006 Serotonin transporter: an example of gene influence on human behaviour. <i>European Neuropsychopharmacology</i> , 2008 , 18, S205-S206	1.2	
215	P.1.a.007 A genetic assessment of antipsychotic and antidepressant cardiac iatrogenicity: focus on the proarrhythmic profile. <i>European Neuropsychopharmacology</i> , 2008 , 18, S206	1.2	
214	TAAR6 variation effect on clinic presentation and outcome in a sample of schizophrenic in-patients: an open label study. <i>European Psychiatry</i> , 2008 , 23, 390-5	6	12
213	5-HT1A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies. <i>International Journal of Neuropsychopharmacology</i> , 2008 , 11, 701-21	5.8	47
212	The serotonin transporter gene and effectiveness of SSRIs. <i>Expert Review of Neurotherapeutics</i> , 2008 , 8, 111-20	4.3	21
211	Pharmacogenetic studies in depression: a proposal for methodologic guidelines. <i>Pharmacogenomics Journal</i> , 2008 , 8, 90-100	3.5	70
210	Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence. <i>CNS Drugs</i> , 2008 , 22, 367-88	6.7	56
209	Strategy for a genetic assessment of antipsychotic and antidepressant-related proarrhythmia. <i>Current Medicinal Chemistry</i> , 2008 , 15, 2472-517	4.3	4
208	The atypical antipsychotics olanzapine and risperidone in the treatment of posttraumatic stress disorder: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials. <i>International Clinical Psychopharmacology</i> , 2008 , 23, 1-8	2.2	53
207	Association analysis of heat shock protein 70 gene polymorphisms in schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2008 , 258, 239-44	5.1	33

206	NOS-I and -III gene variants are differentially associated with facets of suicidal behavior and aggression-related traits. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2008 , 147B, 42-8	3.5	44
205	Dopa decarboxylase and tyrosine hydroxylase gene variants in suicidal behavior. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2008 , 147, 308-15	3.5	13
204	Serotonin transporter gene and adverse life events in adult ADHD. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2008 , 147B, 1461-9	3.5	36
203	Effect of the dysbindin gene on antimanic agents in patients with bipolar I disorder. <i>Psychiatry Investigation</i> , 2008 , 5, 102-5	3.1	4
202	Pharmacogenetics of Antidepressant Response 2008 , 315-353		1
201	Further evidence of MAO-A gene variants associated with bipolar disorder. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2007 , 144B, 37-40	3.5	12
200	HTR2C and HTR1A gene variants in German and Italian suicide attempters and completers. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2007 , 144B, 291-9	3.5	66
199	Effect of 5-haplotype of dysbindin gene (DTNBP1) polymorphisms for the susceptibility to bipolar I disorder. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2007 , 144B, 701-3	3.5	28
198	Actimetric evidence that CLOCK 3111 T/C SNP influences sleep and activity patterns in patients affected by bipolar depression. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2007 , 144B, 631-5	3.5	149
197	Tachykinin receptor 1 variants associated with aggression in suicidal behavior. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2007 , 144B, 757-61	3.5	16
196	Polymorphisms in dopamine receptor DRD1 and DRD2 genes and psychopathological and extrapyramidal symptoms in patients on long-term antipsychotic treatment. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2007 , 144B, 809-15	3.5	36
195	Dissecting the determinants of depressive disorders outcome: an in depth analysis of two clinical cases. <i>Annals of General Psychiatry</i> , 2007 , 6, 5	3.4	8
194	Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. <i>Molecular Psychiatry</i> , 2007 , 12, 247-57	15.1	427
193	HTR2C (cys23ser) polymorphism influences early onset in bipolar patients in a large European multicenter association study. <i>Molecular Psychiatry</i> , 2007 , 12, 797-8	15.1	27
192	A neural network model for combining clinical predictors of antidepressant response in mood disorders. <i>Journal of Affective Disorders</i> , 2007 , 98, 239-45	6.6	17
191	Interaction between serotonin transporter gene, catechol-O-methyltransferase gene and stressful life events in mood disorders. <i>International Journal of Neuropsychopharmacology</i> , 2007 , 10, 437-47	5.8	94
190	Personality and Genetics. <i>Current Psychiatry Reviews</i> , 2007 , 3, 147-159	0.9	6
189	HTR2A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies. <i>Current Medicinal Chemistry</i> , 2007 , 14, 2053-69	4.3	119

188	Depression and social phobia secondary to alcohol dependence. <i>Neuropsychobiology</i> , 2007 , 56, 111-8	4	6
187	No association of TPH1 218A/C polymorphism with treatment response and intolerance to SSRIs in Japanese patients with major depression. <i>Neuropsychobiology</i> , 2007 , 56, 167-71	4	28
186	Genetics of Alzheimer's disease. A rapidly evolving field. <i>Journal of Alzheimer's Disease</i> , 2007 , 12, 73-92	4.3	79
185	Reply to Comments by Dr Rico-Villademoros. <i>Journal of Clinical Psychopharmacology</i> , 2007 , 27, 99	1.7	0
184	Dysbindin associated with selective serotonin reuptake inhibitor antidepressant efficacy. <i>Pharmacogenetics and Genomics</i> , 2007 , 17, 69-75	1.9	23
183	Incomplete coverage of candidate genes: a poorly considered bias. <i>Current Genomics</i> , 2007 , 8, 476-83	2.6	20
182	Serotonin transporter gene influences the time course of improvement of "core" depressive and somatic anxiety symptoms during treatment with SSRIs for recurrent mood disorders. <i>Psychiatry Research</i> , 2007 , 149, 185-93	9.9	39
181	Clinical prediction of antidepressant response in mood disorders: linear multivariate vs. neural network models. <i>Psychiatry Research</i> , 2007 , 152, 223-31	9.9	22
180	Antidepressant response in the elderly. <i>Psychiatry Research</i> , 2007 , 152, 37-44	9.9	15
179	Heat-shock protein-70 genes and response to antidepressants in major depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007 , 31, 1006-11	5.5	31
178	5-HT2A SNPs and the Temperament and Character Inventory. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007 , 31, 1275-81	5.5	31
177	How do genes exert their role? Period 3 gene variants and possible influences on mood disorder phenotypes. <i>European Neuropsychopharmacology</i> , 2007 , 17, 587-94	1.2	52
176	Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. <i>Journal of Clinical Psychiatry</i> , 2007 , 68, 1062-70	4.6	313
175	Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin. <i>Journal of Affective Disorders</i> , 2006 , 90, 251-6	6.6	86
174	Metabolic risk factor profile associated with use of second generation antipsychotics: a cross sectional study in a Community Mental Health Centre. <i>BMC Psychiatry</i> , 2006 , 6, 11	4.2	18
173	Influence of postpartum onset on the course of mood disorders. <i>BMC Psychiatry</i> , 2006 , 6, 4	4.2	14
172	Retrospective analysis of psychomotor agitation, hypomanic symptoms, and suicidal ideation in unipolar depression. <i>Depression and Anxiety</i> , 2006 , 23, 389-97	8.4	36
171	Serotonin transporter gene variants and behavior: a comprehensive review. <i>Current Drug Targets</i> , 2006 , 7, 1659-69	3	169

170 Major depressive disorders: depressive disorders **2006**, 45-73

169 Temperament and character in mood disorders: influence of DRD4, SERTPR, TPH and MAO-A polymorphisms. *Neuropsychobiology*, **2006**, 53, 9-16 4 64

168 S.03.05 Clinical pharmacogenetic studies in the treatment of depression. *European Neuropsychopharmacology*, **2006**, 16, S169 1.2

167 Interleukin-1 alpha and beta, TNF-alpha and HTTLPR gene variants study on alcohol toxicity and detoxification outcome. *Neuroscience Letters*, **2006**, 406, 107-12 3.3 9

166 Pooling pharmacogenetic studies on the serotonin transporter: a mega-analysis. *Psychiatry Research*, **2006**, 145, 61-5 9.9 29

165 Relapse during a 6-month continuation treatment with fluvoxamine in an Italian population: the role of clinical, psychosocial and genetic variables. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2006**, 30, 442-8 5.5 12

164 Serotonin transporter gene-linked polymorphic region: possible pharmacogenetic implications of rare variants. *Psychiatric Genetics*, **2006**, 16, 153-8 2.9 45

163 Lack of genetic association between the phospholipase A2 gene and bipolar mood disorder in a European multicentre case-control study. *Psychiatric Genetics*, **2006**, 16, 169-71 2.9 5

162 Catechol-O-methyltransferase gene variants in mood disorders in the Italian population. *Psychiatric Genetics*, **2006**, 16, 181-2 2.9 28

161 Improvement of cognitive functioning in mood disorder patients with depressive symptomatic recovery during treatment: an exploratory analysis. *Psychiatry and Clinical Neurosciences*, **2006**, 60, 598-604 6.2 29

160 Ethical problems in pharmacogenetic studies of psychiatric disorders. *Pharmacogenomics Journal*, **2006**, 6, 289-95 3.5 8

159 Interaction analysis between 5-HTTLPR and TNFA -238/-308 polymorphisms in schizophrenia. *Journal of Neural Transmission*, **2006**, 113, 887-97 4.3 14

158 Cognitive Status, Depressive Symptoms, and Health Status as Predictors of Functional Disability Among Elderly Persons With Low-to-Moderate Education: The Faenza Community Aging Study. *American Journal of Geriatric Psychiatry*, **2005**, 13, 672-685 6.5 10

157 Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-beta -50 T/C SNP. *Neuroscience Letters*, **2005**, 376, 51-5 3.3 164

156 No evidence for interaction between 5-HT2A receptor and serotonin transporter genes in schizophrenia. *Neuroscience Research*, **2005**, 52, 195-9 2.9 14

155 Polymorphisms of heat shock protein 70 gene (HSPA1A, HSPA1B and HSPA1L) and schizophrenia. *Neuroscience Research*, **2005**, 53, 8-13 2.9 31

154 The influence of Serotonin Transporter Promoter Polymorphism (SERTPR) and other polymorphisms of the serotonin pathway on the efficacy of antidepressant treatments. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2005**, 29, 1074-84 5.5 92

153 Social adjustment could be associated with the serotonin transporter gene in remitted patients with mood disorders and healthy subjects. *Psychiatry Research*, **2005**, 134, 191-4 9.9 9

152	Sertraline versus fluvoxamine in the treatment of elderly patients with major depression: a double-blind, randomized trial. <i>Journal of Clinical Psychopharmacology</i> , 2005 , 25, 471-5	1.7	24
151	Genetics of Mood Disorders 2005 , 35-75		1
150	Two new rare variants in the circadian "clock" gene may influence sleep pattern. <i>Genetics in Medicine</i> , 2005 , 7, 455-7	8.1	13
149	Pharmacogenetics in the treatment of depression: pharmacodynamic studies. <i>Pharmacogenetics and Genomics</i> , 2005 , 15, 61-7	1.9	64
148	Association between COMT (Val158Met) functional polymorphism and early onset in patients with major depressive disorder in a European multicenter genetic association study. <i>Molecular Psychiatry</i> , 2005 , 10, 598-605	15.1	119
147	Dopamine transporter haplotype and attention-deficit hyperactivity disorder. <i>Molecular Psychiatry</i> , 2005 , 10, 617-8	15.1	22
146	Profiles of "manic" symptoms in bipolar I, bipolar II and major depressive disorders. <i>Journal of Affective Disorders</i> , 2005 , 84, 159-66	6.6	75
145	Components of self-esteem in affective patients and non-psychiatric controls. <i>Journal of Affective Disorders</i> , 2005 , 88, 93-8	6.6	25
144	5-HT 1A polymorphism and self-transcendence in mood disorders. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2005 , 137B, 33-5	3.5	24
143	Insomnia improvement during antidepressant treatment and CLOCK gene polymorphism. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2005 , 137B, 36-9	3.5	117
142	Genes involved in Alzheimer's disease, a survey of possible candidates. <i>Journal of Alzheimer's Disease</i> , 2005 , 7, 331-53	4.3	29
141	Interaction between the tryptophan hydroxylase gene and the serotonin transporter gene in schizophrenia but not in bipolar or unipolar affective disorders. <i>Neuropsychobiology</i> , 2005 , 51, 3-9	4	14
140	Occurrence of cognitive impairment and dementia after the age of 60: a population-based study from Northern Italy. <i>Dementia and Geriatric Cognitive Disorders</i> , 2005 , 19, 97-105	2.6	70
139	New antipsychotics and schizophrenia: a review on efficacy and side effects. <i>Current Medicinal Chemistry</i> , 2004 , 11, 343-58	4.3	87
138	BanI polymorphism of the cytosolic phospholipase A2 gene and mood disorders in the Korean population. <i>Neuropsychobiology</i> , 2004 , 49, 185-8	4	31
137	The 5-HT _{2C} receptor as a target for mood disorders. <i>Expert Opinion on Therapeutic Targets</i> , 2004 , 8, 15-26.4		43
136	Serotonin transporter 5HTTLPR polymorphism and affective disorders: no evidence of association in a large European multicenter study. <i>European Journal of Human Genetics</i> , 2004 , 12, 377-82	5.3	73
135	The pharmacogenomics of selective serotonin reuptake inhibitors. <i>Pharmacogenomics Journal</i> , 2004 , 4, 233-44	3.5	57

134	Further evidence for a possible association between serotonin transporter gene and lithium prophylaxis in mood disorders. <i>Pharmacogenomics Journal</i> , 2004 , 4, 267-73	3.5	51
133	Social adjustment and self-esteem of bipolar patients: a multicentric study. <i>Journal of Affective Disorders</i> , 2004 , 79, 97-103	6.6	68
132	From molecular biology to pharmacogenetics: a review of the literature on antidepressant treatment and suggestions of possible candidate genes. <i>Psychopharmacology</i> , 2004 , 174, 490-503	4.7	40
131	Genetic features of antidepressant induced mania and hypo-mania in bipolar disorder. <i>Psychopharmacology</i> , 2004 , 174, 504-11	4.7	36
130	Neural network analysis in pharmacogenetics of mood disorders. <i>BMC Medical Genetics</i> , 2004 , 5, 27	2.1	37
129	Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders. <i>American Journal of Medical Genetics Part A</i> , 2004 , 129B, 36-40		61
128	Paroxetine in the treatment of depressed patients with haematological malignancy: an open-label study. <i>Human Psychopharmacology</i> , 2004 , 19, 25-9	2.3	8
127	Tumor necrosis factor alpha gene-G308A polymorphism associated with bipolar I disorder in the Korean population. <i>Psychiatry Research</i> , 2004 , 125, 65-8	9.9	33
126	Dimensions of major psychoses: a confirmatory factor analysis of six competing models. <i>Psychiatry Research</i> , 2004 , 127, 101-9	9.9	46
125	Depressive syndrome in major psychoses: a study on 1351 subjects. <i>Psychiatry Research</i> , 2004 , 127, 85-99	9.9	45
124	Monocyte chemoattractant protein-1 (MCP1) promoter -2518 polymorphism may confer a susceptibility to major depressive disorder in the Korean population. <i>Psychiatry Research</i> , 2004 , 127, 279-81	9.9	29
123	A single nucleotide polymorphism in glycogen synthase kinase 3-beta promoter gene influences onset of illness in patients affected by bipolar disorder. <i>Neuroscience Letters</i> , 2004 , 355, 37-40	3.3	143
122	DRD4 exon 3 variants are not associated with symptomatology of major psychoses in a German population. <i>Neuroscience Letters</i> , 2004 , 368, 269-73	3.3	5
121	A glycogen synthase kinase 3-beta promoter gene single nucleotide polymorphism is associated with age at onset and response to total sleep deprivation in bipolar depression. <i>Neuroscience Letters</i> , 2004 , 368, 123-6	3.3	168
120	Monocyte chemoattractant protein-1 promoter -2518 polymorphism and schizophrenia in the Korean population. <i>Psychiatric Genetics</i> , 2004 , 14, 65-7	2.9	14
119	Pharmacogenetics of selective serotonin reuptake inhibitor response: a 6-month follow-up. <i>Pharmacogenetics and Genomics</i> , 2004 , 14, 607-13		28
118	The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings. <i>International Journal of Neuropsychopharmacology</i> , 2004 , 7, 453-60	5.8	109
117	Tardive dyskinesia and DRD2, DRD3, DRD4, 5-HT2A variants in schizophrenia: an association study with repeated assessment. <i>International Journal of Neuropsychopharmacology</i> , 2004 , 7, 489-93	5.8	41

116	Glutathione S-transferase M1 polymorphism may contribute to schizophrenia in the Korean population. <i>Psychiatric Genetics</i> , 2004 , 14, 147-50	2.9	28
115	The Use of DNA Microarray in the Pharmacogenetics of Antidepressants: Guidelines for a Targeted Approach. <i>Current Genomics</i> , 2004 , 5, 499-508	2.6	2
114	. <i>Psychiatric Genetics</i> , 2003 , 13, 121-126	2.9	4
113	Genetic association between the phospholipase A2 gene and unipolar affective disorder: a multicentre case-control study. <i>Psychiatric Genetics</i> , 2003 , 13, 211-20	2.9	20
112	Possible association between -G308A tumour necrosis factor-alpha gene polymorphism and major depressive disorder in the Korean population. <i>Psychiatric Genetics</i> , 2003 , 13, 179-81	2.9	90
111	Comparison of response to fluvoxamine in nondemented elderly compared to younger patients affected by major depression. <i>Journal of Clinical Psychopharmacology</i> , 2003 , 23, 535-9	1.7	18
110	Multicentre Italian family-based association study on tyrosine hydroxylase, catechol-O-methyl transferase and Wolfram syndrome 1 polymorphisms in mood disorders. <i>Psychiatric Genetics</i> , 2003 , 13, 121-6	2.9	24
109	Influence of CLOCK gene polymorphism on circadian mood fluctuation and illness recurrence in bipolar depression. <i>American Journal of Medical Genetics Part A</i> , 2003 , 123B, 23-6		233
108	Genetic dissection of psychopathological symptoms: insomnia in mood disorders and CLOCK gene polymorphism. <i>American Journal of Medical Genetics Part A</i> , 2003 , 121B, 35-8		184
107	Interleukin-10 gene promoter polymorphism is not associated with schizophrenia in the Korean population. <i>Psychiatry and Clinical Neurosciences</i> , 2003 , 57, 153-9	6.2	14
106	Tumor necrosis factor-alpha gene polymorphism at position -308 and schizophrenia in the Korean population. <i>Psychiatry and Clinical Neurosciences</i> , 2003 , 57, 399-403	6.2	26
105	Lack of association between the 5HT2A receptor polymorphism (T102C) and unipolar affective disorder in a multicentric European study. <i>European Neuropsychopharmacology</i> , 2003 , 13, 365-8	1.2	17
104	Antidepressant effects of light therapy combined with sleep deprivation are influenced by a functional polymorphism within the promoter of the serotonin transporter gene. <i>Biological Psychiatry</i> , 2003 , 54, 687-92	7.9	73
103	TNFB polymorphism may be associated with schizophrenia in the Korean population. <i>Schizophrenia Research</i> , 2003 , 61, 39-45	3.6	15
102	SSRIs antidepressant activity is influenced by G beta 3 variants. <i>European Neuropsychopharmacology</i> , 2003 , 13, 117-22	1.2	82
101	Association study between glutathione S-transferase P1 polymorphism and schizophrenia in the Korean population. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2003 , 27, 519-23	5.5	20
100	Clinical features of antidepressant associated manic and hypomanic switches in bipolar disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2003 , 27, 751-7	5.5	24
99	Dopamine receptor D2 and D3 gene variants are not associated with the antidepressant effect of total sleep deprivation in bipolar depression. <i>Psychiatry Research</i> , 2003 , 118, 241-7	9.9	21

98	Gene-environment interaction in psychiatric disorders as indicated by season of birth variations in tryptophan hydroxylase (TPH), serotonin transporter (5-HTTLPR) and dopamine receptor (DRD4) gene polymorphisms. <i>Psychiatry Research</i> , 2003 , 119, 99-111	9.9	64
97	Predicting response to lithium in mood disorders: role of genetic polymorphisms. <i>Molecular Diagnosis and Therapy</i> , 2003 , 3, 17-30		21
96	VNTR polymorphism of tyrosine hydroxylase gene and schizophrenia in the Korean population. <i>Neuropsychobiology</i> , 2003 , 47, 131-6	4	5
95	Polymorphism of the serotonin transporter gene and symptomatic dimensions of schizophrenia in the Korean population. <i>Neuropsychobiology</i> , 2003 , 47, 182-6	4	17
94	Pharmacogenetics in affective disorders. <i>European Journal of Pharmacology</i> , 2002 , 438, 117-28	5.3	44
93	Positive association of dopamine D2 receptor polymorphism with bipolar affective disorder in a European multicenter association study of affective disorders. <i>American Journal of Medical Genetics Part A</i> , 2002 , 114, 177-185		46
92	Family-based association study of 5-HTTLPR, TPH, MAO-A, and DRD4 polymorphisms in mood disorders. <i>American Journal of Medical Genetics Part A</i> , 2002 , 114, 361-9		57
91	Pharmacogenetics of lithium prophylaxis in mood disorders: analysis of COMT, MAO-A, and Gbeta3 variants. <i>American Journal of Medical Genetics Part A</i> , 2002 , 114, 370-9		46
90	Association study of MAO-A, COMT, 5-HT2A, DRD2, and DRD4 polymorphisms with illness time course in mood disorders. <i>American Journal of Medical Genetics Part A</i> , 2002 , 114, 380-90		43
89	Excess of allele1 for alpha3 subunit GABA receptor gene (GABRA3) in bipolar patients: a multicentric association study. <i>Molecular Psychiatry</i> , 2002 , 7, 201-7	15.1	48
88	Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity. <i>International Journal of Neuropsychopharmacology</i> , 2002 , 5, 27-35	5.8	78
87	Serotonin transporter gene (5-HTTLPR) and major psychoses. <i>Molecular Psychiatry</i> , 2002 , 7, 95-9	15.1	76
86	Lithium long-term treatment in mood disorders: clinical and genetic predictors. <i>Pharmacogenomics</i> , 2002 , 3, 117-29	2.6	12
85	Clinical and demographic features of mood disorder subtypes. <i>Psychiatry Research</i> , 2002 , 112, 195-210	9.9	48
84	Rapid cycling mood disorder: clinical and demographic features. <i>Comprehensive Psychiatry</i> , 2002 , 43, 336-43	7.3	14
83	Seasonal variations of lithium plasma levels. <i>Psychiatry Research</i> , 2002 , 111, 35-41	9.9	10
82	Positive association of dopamine D2 receptor polymorphism with bipolar affective disorder in a European Multicenter Association Study of affective disorders. <i>American Journal of Medical Genetics Part A</i> , 2002 , 114, 177-85		10
81	Major psychoses symptomatology: factor analysis of 2241 psychotic subjects. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2001 , 251, 193-8	5.1	34

80	DRD4 exon 3 variants associated with delusional symptomatology in major psychoses: a study on 2,011 affected subjects. <i>American Journal of Medical Genetics Part A</i> , 2001 , 105, 283-90		54
79	Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. <i>Molecular Psychiatry</i> , 2001 , 6, 586-92	15.1	153
78	Variability of 5-HT _{2C} receptor cys23ser polymorphism among European populations and vulnerability to affective disorder. <i>Molecular Psychiatry</i> , 2001 , 6, 579-85	15.1	138
77	Influence of 5-HTTLPR and TPH variants on illness time course in mood disorders. <i>Journal of Psychiatric Research</i> , 2001 , 35, 217-23	5.2	37
76	Serotonin transporter gene associated with lithium prophylaxis in mood disorders. <i>Pharmacogenomics Journal</i> , 2001 , 1, 71-7	3.5	103
75	Tryptophan hydroxylase gene associated with paroxetine antidepressant activity. <i>European Neuropsychopharmacology</i> , 2001 , 11, 375-80	1.2	88
74	Tryptophan hydroxylase polymorphism and suicidality in unipolar and bipolar affective disorders: a multicenter association study. <i>Biological Psychiatry</i> , 2001 , 49, 405-9	7.9	61
73	Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. <i>Biological Psychiatry</i> , 2001 , 50, 323-30	7.9	197
72	Tryptophan hydroxylase gene and major psychoses. <i>Psychiatry Research</i> , 2001 , 103, 79-86	9.9	47
71	No association between dopamine D(2) and D(4) receptor gene variants and antidepressant activity of two selective serotonin reuptake inhibitors. <i>Psychiatry Research</i> , 2001 , 104, 195-203	9.9	49
70	Melancholic features and response to lithium prophylaxis in mood disorders. <i>Depression and Anxiety</i> , 2000 , 11, 73-9	8.4	13
69	Serotonin-2A receptor gene is not associated with symptomatology of schizophrenia 2000 , 96, 84-87		16
68	A European multicenter association study of HTR2A receptor polymorphism in bipolar affective disorder 2000 , 96, 136-140		35
67	Serotonin-2C and serotonin-1A receptor genes are not associated with psychotic symptomatology of mood disorders. <i>American Journal of Medical Genetics Part A</i> , 2000 , 96, 161-6		19
66	Effect of reboxetine augmentation in SSRI resistant patients. <i>Human Psychopharmacology</i> , 2000 , 15, 143-145	2.3	16
65	Dopamine receptor D2 Ser/Cys 311 variant is associated with delusion and disorganization symptomatology in major psychoses. <i>Molecular Psychiatry</i> , 2000 , 5, 270-4	15.1	53
64	Linkage of mood disorders with D2, D3 and TH genes: a multicenter study. <i>Journal of Affective Disorders</i> , 2000 , 58, 51-61	6.6	24
63	Serotonin receptor 2A, 2C, 1A genes and response to lithium prophylaxis in mood disorders. <i>Journal of Psychiatric Research</i> , 2000 , 34, 89-98	5.2	63

62	Patterns of symptom improvement during antidepressant treatment of delusional depression. <i>Psychiatry Research</i> , 2000 , 94, 185-90	9.9	26
61	Impact of clinical variables on illness time course in mood disorders. <i>Psychiatry Research</i> , 2000 , 97, 217-23	9.9	24
60	Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. <i>Journal of Clinical Psychiatry</i> , 2000 , 61, 26-9	4.6	180
59	Adaptaci3n social y autoestima en pacientes con remisi3n de trastorno del estado de 3imo. <i>European Psychiatry (Ed Espa3ola)</i> , 2000 , 7, 26-32		
58	A European multicenter association study of HTR2A receptor polymorphism in bipolar affective disorder 2000 , 96, 136		2
57	Serotonin-2A receptor gene is not associated with symptomatology of schizophrenia. <i>American Journal of Medical Genetics Part A</i> , 2000 , 96, 84-7		2
56	Further evidence supporting the association between the dopamine receptor D2 Ser/Cys311 variant and disorganized symptomatology of schizophrenia. <i>Schizophrenia Research</i> , 2000 , 43, 161-2	3.6	7
55	Genetic variants of dopamine receptor D4 and psychopathology. <i>Schizophrenia Bulletin</i> , 1999 , 25, 609-18	1.3	32
54	Serotonin transporter gene (5-HTTLPR) is not associated with depressive symptomatology in mood disorders. <i>Molecular Psychiatry</i> , 1999 , 4, 280-3	15.1	89
53	Symptomatologic analysis of psychotic and non-psychotic depression. <i>Journal of Affective Disorders</i> , 1999 , 54, 183-7	6.6	51
52	Delineating psychopathologic clusters within dysthymia: a study of 512 out-patients without major depression. <i>Journal of Affective Disorders</i> , 1999 , 56, 17-25	6.6	42
51	Tryptophan hydroxylase gene and response to lithium prophylaxis in mood disorders. <i>Journal of Psychiatric Research</i> , 1999 , 33, 371-7	5.2	77
50	No interaction of GABAA alpha-1 subunit and dopamine receptor D4 exon 3 genes in symptomatology of major psychoses 1999 , 88, 44-49		15
49	Dopamine D2 receptor gene not associated with symptomatology of mood disorders. <i>American Journal of Medical Genetics Part A</i> , 1999 , 88, 294-297		14
48	Dopamine D3 receptor gene not associated with symptomatology of major psychoses 1999 , 88, 476-480		12
47	No interaction between serotonin transporter gene and dopamine receptor D4 gene in symptomatology of major psychoses 1999 , 88, 481-485		9
46	Dopamine receptor D4 gene is not associated with major psychoses 1999 , 88, 486-491		21
45	Tyrosine hydroxylase polymorphism and phenotypic heterogeneity in bipolar affective disorder: a multicenter association study. <i>American Journal of Medical Genetics Part A</i> , 1999 , 88, 527-32		15

44	Outcome of affective psychosis 1999 , 10, 50-54		6
43	Serotonin transporter gene not associated with psychotic symptomatology of mood disorders. <i>Psychiatry Research</i> , 1999 , 86, 59-65	9.9	21
42	No association between serotonin-2A receptor gene polymorphism and psychotic symptomatology of mood disorders. <i>Psychiatry Research</i> , 1999 , 86, 203-9	9.9	12
41	Dopamine receptor D2 and D4 genes, GABA(A) alpha-1 subunit genes and response to lithium prophylaxis in mood disorders. <i>Psychiatry Research</i> , 1999 , 87, 7-19	9.9	62
40	Dopamine receptor D4 is not associated with antidepressant activity of sleep deprivation. <i>Psychiatry Research</i> , 1999 , 89, 107-14	9.9	26
39	Factor analysis of delusional disorder symptomatology. <i>Comprehensive Psychiatry</i> , 1999 , 40, 143-7	7.3	34
38	Clinical and demographic features of psychotic and nonpsychotic depression. <i>Comprehensive Psychiatry</i> , 1999 , 40, 358-62	7.3	29
37	Serotonin transporter gene is not associated with symptomatology of schizophrenia. <i>Schizophrenia Research</i> , 1999 , 35, 33-9	3.6	28
36	Lack of association between tryptophan hydroxylase gene and psychotic symptomatology in schizophrenia. <i>Schizophrenia Research</i> , 1999 , 40, 171-2	3.6	6
35	Social adjustment and self-esteem in remitted patients with mood disorders. <i>European Psychiatry</i> , 1999 , 14, 137-42	6	32
34	Factor analysis of mania. <i>Archives of General Psychiatry</i> , 1999 , 56, 671-2		33
33	No interaction of GABA(A) alpha-1 subunit and dopamine receptor D4 exon 3 genes in symptomatology of major psychoses. <i>American Journal of Medical Genetics Part A</i> , 1999 , 88, 44-9		2
32	Dopamine D2 receptor gene not associated with symptomatology of mood disorders. <i>American Journal of Medical Genetics Part A</i> , 1999 , 88, 294-7		1
31	Outcome of affective psychosis. <i>Depression and Anxiety</i> , 1999 , 10, 50-4	8.4	1
30	Influence of a functional polymorphism within the promoter of the serotonin transporter gene on the effects of total sleep deprivation in bipolar depression. <i>American Journal of Psychiatry</i> , 1999 , 156, 1450-2	11.9	113
29	Tyrosine hydroxylase gene in linkage disequilibrium with mood disorders. <i>Molecular Psychiatry</i> , 1998 , 3, 169-74	15.1	15
28	Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. <i>Journal of Psychiatric Research</i> , 1998 , 32, 255-9	5.2	134
27	Mode of inheritance in mood disorder families according to fluvoxamine response. <i>Acta Psychiatrica Scandinavica</i> , 1998 , 98, 443-50	6.5	52

26	Analysis of depressive symptomatology in mood disorders. <i>Depression and Anxiety</i> , 1998 , 8, 80-85	8.4	29
25	Tyrosine hydroxylase gene associated with depressive symptomatology in mood disorder 1998 , 81, 127-130		40
24	Dopamine receptor D4 gene is associated with delusional symptomatology in mood disorders. <i>Psychiatry Research</i> , 1998 , 80, 129-36	9.9	34
23	Self-esteem in remitted patients with mood disorders is not associated with the dopamine receptor D4 and the serotonin transporter genes. <i>Psychiatry Research</i> , 1998 , 80, 137-44	9.9	6
22	Dopamine receptor D2 Ser/Cys311 variant associated with disorganized symptomatology of schizophrenia. <i>Schizophrenia Research</i> , 1998 , 34, 207-10	3.6	38
21	Psychopathology of dysthymia. <i>European Psychiatry</i> , 1998 , 13, 258s-258s	6	
20	Dopamine receptor D3 gene and response to lithium prophylaxis in mood disorders. <i>International Journal of Neuropsychopharmacology</i> , 1998 , 1, 125-129	5.8	40
19	European Collaborative Project on Affective Disorders: interactions between genetic and psychosocial vulnerability factors. <i>Psychiatric Genetics</i> , 1998 , 8, 197-205	2.9	40
18	GABAA alpha-1 subunit gene not associated with depressive symptomatology in mood disorders. <i>Psychiatric Genetics</i> , 1998 , 8, 251-4	2.9	20
17	Analysis of depressive symptomatology in mood disorders. <i>Depression and Anxiety</i> , 1998 , 8, 80-5	8.4	4
16	S.17.05 Molecular genetics of bipolar disorders: Implication for psychotropic drugs. <i>European Neuropsychopharmacology</i> , 1997 , 7, S112-S113	1.2	4
15	Evidence for an association between the dopamine D3 receptor gene DRD3 and schizophrenia. <i>Human Heredity</i> , 1997 , 47, 6-16	1.1	51
14	Effects of fluoxetine at antidepressant doses on short-term outcome of detoxified alcoholics. <i>International Clinical Psychopharmacology</i> , 1996 , 11, 109-117	2.2	12
13	Identification of symptomatologic patterns common to major psychoses: proposal for a phenotype definition. <i>American Journal of Medical Genetics Part A</i> , 1996 , 67, 393-400		51
12	Effects of fluoxetine at antidepressant doses on short-term outcome of detoxified alcoholics. <i>International Clinical Psychopharmacology</i> , 1996 , 11, 109-17	2.2	36
11	Low-dose buprenorphine detoxification in long term methadone addicts. <i>Regulatory Peptides</i> , 1994 , 53, S289-S290		5
10	Opiate detoxification of methadone maintenance patients using lefetamine, clonidine and buprenorphine. <i>Drug and Alcohol Dependence</i> , 1994 , 36, 139-45	4.9	60
9	"Separation" of the mother-child couple: pregnancy and maternity of drug-dependent women. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 1994 , 404, 47-53	3.1	6

8 Gene-Environment Interaction Studies in Suicidal Behaviour. *Advances in Biological Psychiatry*,63-74

7 Genome-Wide Association Identifies the First Risk Loci for Psychosis in Alzheimer Disease 1

6 Serotonin transporter gene (5-HTTLPR) and major psychoses 5

5 Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder 4

4 Genetic and clinical characteristics of treatment-resistant depression using primary care records in two UK cohorts 3

3 Dissecting the shared genetic architecture of suicide attempt, psychiatric disorders and known risk factors 2

2 Genetic underpinnings of sociability in the UK Biobank 2

1 Depressive symptoms and neuroticism-related traits are the main factors associated with wellbeing independent of the history of lifetime depression in the UK Biobank. *Psychological Medicine*,1-9 6.9